

Call text: 13<sup>th</sup> JPIAMR transnational co-funded call for research projects within the ERA-NET JPIAMR-ACTION:

## “One Health interventions to prevent or reduce the development and transmission of antimicrobial resistance (AMR)”

---

### History of the modifications

18/01/21: Modification of the national annexes (AEI, Spain)

---

**Short title: “HARISSA”: One HeAlth InteRvention and TransmiSSion in AMR**

Antimicrobial resistance (AMR) does not recognise geographic borders or species barriers. Progress on AMR is necessary to achieve the United Nations (UN) Sustainable Development Goals (SDGs), with AMR being deeply rooted into attainment of SDGs promoting no poverty, good health and wellbeing, zero hunger, reduced inequality and decent work and international growth. With the current focus of the JPIAMR Strategic Research and Innovation Agenda, this call will specifically focus on tackling the rising threat of antibiotic resistance. Addressing the rising threat of antibiotic resistance requires a One Health approach since resistant bacteria, genetic elements and antibiotics are found in humans, animals and the environment. Declining clinical effectiveness of existing antibiotics together with the low and insufficient number of promising new antibiotics in the pipeline stresses the urgency to understand the mechanisms of emergence and transmission of antibiotic resistance. The European One Health Action Plan against AMR<sup>1</sup> encourages the EU and its Member States to deliver innovative, effective and sustainable responses to AMR, especially to reduce the emergence and spread of AMR inside and outside the EU. This call, funded under the ERA-NET JPIAMR-ACTION, is the 13th JPIAMR transnational call for research projects. The call advocates for a One Health approach to 1) understand the impact of interventions on the development and transmission of antibiotic resistance and to 2) design, implement, evaluate, and compare interventions that will have a true impact on preventing or reducing the development and transmission of antibiotic resistance in and between the different One Health settings (human, animal, environment).

Research is needed to understand antibiotic resistance development and transmission and to develop interventions in various geographic and socio-economic settings, to design One Health implementation strategies, and to test their cost effectiveness, efficiency and uptake<sup>2</sup>. Factors including the heterogeneity of culture and behaviour, healthcare systems, prescribing practices and consumption of antibiotics, water utility and sanitary routines, agricultural practices, pharmaceutical manufacturing processes, sewage/effluent management and treatment, and resistance to antibiotics across the globe, including in low and middle income countries (LMICs), warrant different implementation approaches.

In addition to inviting researchers from participating countries, this call intends to support and increase the participation and leadership of researchers from LMICs<sup>3</sup> in transnational research

---

<sup>1</sup> [https://ec.europa.eu/health/sites/health/files/antimicrobial\\_resistance/docs/amr\\_2017\\_action-plan.pdf](https://ec.europa.eu/health/sites/health/files/antimicrobial_resistance/docs/amr_2017_action-plan.pdf)

<sup>2</sup> <http://www.who.int/antimicrobial-resistance/global-action-plan/en/>

<sup>3</sup> <http://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/DAC-List-ODA-Recipients-for-reporting-2021-flows.pdf>

---

projects. Antibiotic resistance thrives in settings with limited access to water and sanitation, medicines, veterinary and human health care, and in geographic locations where antibiotics are produced and used and pose increased and unknown risks for humans, animals and the environment. Research and innovation in these types of settings, often prevailing in resource-limited contexts, are essential to prevent or reduce the local development and transmission of antibiotic resistance and is of great importance for our collective global future.

## 1. Aim of the call

The primary aim of the [ERA-Net JPIAMR-ACTION co-funded call](#) is to 1) understand the impact of interventions on the development and transmission of antibiotic resistance and to 2) design, implement, evaluate, and compare interventions that will have a true impact on reducing the development and transmission of antibiotic resistance in and between the different One Health settings. Projects should be implemented into relevant geographic areas, including into resource-limited settings, with a One Health perspective. Projects are encouraged to include transdisciplinary research teams, in which involvement of the social sciences is also encouraged. LMIC-led collaborations at global and regional level are welcomed.

### 1.1 Topics of the call

This call advocates for a One Health approach. Proposals should focus on at least two One Health settings<sup>4</sup> (human, animal, environment) and should aim to either:

- Understand the impact of interventions on the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings;

OR

- Design, implement, evaluate, and/or compare innovative interventions to control the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings.

The studied intervention(s) should bring new research insights. This also means avoiding duplication of recent research already undertaken or ongoing that incorporates the scope of the scientific topic areas in this call.

Proposals are encouraged to consider the use of interventions with a potential broad impact, including for LMICs.

For any project applying for funding to support a clinical study, please check the National Rules and Requirements (Annex B) to see if this is eligible for funding. For some funders, a trial to test (the effectiveness of) the intervention could be eligible.

The following sub-topics are **out of scope** of the call:

- Proposals not primarily focusing on antibiotic resistance.
- Proposals limited to implementing existing interventions to new countries without any research objectives.
- Development of new antimicrobial drugs or investigations on new targets for the development of antimicrobial drugs.
- Proposals solely developing diagnostic tools to monitor selection or transmission of antibiotic resistance.

---

<sup>4</sup> Consult the National Rules and Requirements (Annex B) to verify what scope of One Health settings is eligible for funding for the different consortium partners.  
Call Text 13<sup>th</sup> JPIAMR transnational co-funded call for research projects within the ERA-NET JPIAMR ACTION

- Proposals aiming to improve existing commercially exploited technologies or products. Proposals solely aiming to develop or implement surveillance systems.

## 2. Application

### 2.1 Eligibility

Applicants must adhere to the specific regulations of their national funding organisations. Therefore, each partner is strongly advised to check carefully the national eligibility rules defined by its own funding organisation, as specified in the National and Regional Requirements (see Annex B). Also see figure 1 below, a checklist for composing an eligible consortium.

Eligibility rules for the consortia are:

- The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different countries (at least two from EU Member States or Associated Countries<sup>5</sup>).
- Maximum of six (6) project partners (including non-funded partners, see figure 1 below). The maximum number of partners can be increased to seven (7) if partners from under represented countries<sup>6</sup> (including LMICs<sup>7</sup>) are included in the consortium.
- Additional National Rules and Regulations of funders may also apply and must be respected, and can be found in Annex B.
- Project partners not eligible for funding (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding organisations) may be involved in projects if they bring their own funding. The budget of non-funded partners shall not exceed 30% of the total transnational project budget requested.
- Consortia should always consist of a majority of project partners eligible for funding according to the criteria above.
- Project partners not eligible to be funded cannot be consortium coordinators and, like funded members, must accept all JPIAMR rules and guidelines.
- At both the pre- and full proposal stage, all partners, including non-funded partners, must submit a signed letter of intent along with their pre-/full proposal. In absence of these letters, the proposal will be declared ineligible.

Encouraged:

- Participation of partners from LMICs.
- Projects engaging end users and stakeholders, for example policy makers, industry and/or patient organisation, etc.<sup>8</sup>.
- Participation in widening mechanisms (see 2.2. below)


<sup>5</sup> <https://ec.europa.eu/research/horizon2020/index.cfm?pg=country-profiles> Note: UK is an EU country for the purposes of this call.

<sup>6</sup> LMICs, Hungary, Latvia, Lithuania, Poland,

<sup>7</sup> LMICs can be funded by Sida, ICARS, and IDRC. For details please consult Annex B.

<sup>8</sup> Funding for academic research in partnership with industry undertaken in the EU must comply with EU state aid rules which state that it is illegal for EU countries to give financial help to some companies and not others in a way which would distort fair competition.

Figure 1. Consortium eligibility checklist



## 2.2. Widening

In order to promote inclusiveness and ensure global participation, relevance and impact of the submitted projects in and outside Europe, the Joint Call will implement a number of widening mechanisms before the evaluation of the full proposals:

- **At the pre-proposal stage**, the widening mechanism will apply to underrepresented countries listed in footnote 6 and 7 in section 2.1. Consortia including a research team from an underrepresented country have the opportunity to increase the total number of partners of the consortium to the maximum of seven (7).

- **At the full proposal stage**, the widening mechanism will no longer be restricted to underrepresented countries but will also include undersubscribed organisations, i.e. funding organisations that will most likely not use the budgets they dedicated to the call. The Call Steering Group will decide on the final list of undersubscribed organisations after the evaluation of pre-proposals. Consortia which are invited to the second stage of the call and which consist of fewer than seven (7) members (being the maximum) will be able to increase the initial size of their consortia **by adding one new partner** eligible for funding by an undersubscribed organisation from the list.

The JCS will include information about the undersubscribed organisations in the invitation letters to the coordinators. The teams eligible for funding by undersubscribed organisations will be able to publish their expressions of interest in the online Partner Search Tool (PST). The JCS and the undersubscribed organisations will promote the use of the PST for widening, but coordinators will be free to also invite new partners who are not registered in the tool. In any case, new partners can only join consortia after their respective undersubscribed organisation confirms that they are indeed eligible under the national regulations. The undersubscribed organisations will inform the JCS of all new partners cleared to join at the full proposal stage.

### **2.3 Submission of joint transnational proposal**

Submissions of proposals will take place in two steps; a pre-proposal and a full proposal phase. In both cases, one joint proposal document (in English, and following the provided template) shall be prepared by the project participants of a joint transnational proposal. The pre-proposal must be submitted by the coordinator before **March 16<sup>th</sup>, 2021 12:00 PM CET** using the [submission platform](#).

In addition, some funding organisations may require the submission of other documents at the national level - either at the first and/or second step. Details can be found in Annex B.

The two-step application process (pre-proposal, full proposal) will have the following targeted timetable:

November 18 2020	Preannouncement: Antibiotic Awareness Day 2020
January 14 2021	Publication of the JPIAMR-ACTION ERA-NET 2021 Call
January 28 2021	Interactive webinar presentation of the call and matchmaking tool.
March 16 2021	Submission deadline for pre-proposals
May 28 2021	Full proposal invitations sent to project coordinators
July 12 2021	Submission deadline for full proposals
September 30 2021	Final funding decision taken by the participating funding organisations
End October 2021	Final funding decision announced to applicants
Mid-November 2021	Publication of results: Antibiotic Awareness Day 2021
	Start of funding

## 2.4 Financial modalities and funding prerequisites

Funding is granted for a maximum of three years in accordance with national regulations and applicable legal provisions. Applicants must comply with their own specific national regulations and scientific remits as detailed in the National and Regional Requirements or specific regulations of their corresponding funding organisation (see Annex B).

The financial indicative commitments made by the funding organisations are listed in the table below. Each country will fund its own approved project partners.

### Anticipated indicative funding provided by each funding organisation

Country	Name of Organisation	Acronym	Contribution (M€)
Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas	CONICET	0,1
Belgium	Fonds voor Wetenschappelijk onderzoek-Vlaanderen	FWO	0,7
Belgium	Fonds de la Recherche Scientifique	FNRS	0,2
Canada	Canadian Institutes of Health Research	CIHR	2,2M CAD\$ (approx. 1,423M€)
Canada	International Development Research Centre	IDRC	1M CAD\$
Denmark	International Centre for Antimicrobial Resistance Solutions	ICARS	1
Denmark	Innovationsfonden	IFD	1
Estonia	ESTONIAN RESEARCH COUNCIL	ETAg	0,1
Finland	Suomen Akatemia	AKA	0,6
France	Agence Nationale de la Recherche	ANR	2
Germany	Federal Ministry of Education and Research	BMBF	3
Hungary	NATIONAL RESEARCH, DEVELOPMENT AND INNOVATION OFFICE	NKFIH	0,3
Ireland	The Health Research Board	HRB	0,37
Ireland	Department of Agriculture, Food and the Marine	DAFM	0,25
Israel	Chief Scientist Office, Ministry of Health	CSO-MOH	0,3
Italy	Fondazione Regionale per la Ricerca Biomedica	FRRB	1
Italy	Ministero della Salute	It-MoH	0,75
Latvia	Valsts Izglitibas Attistibas Ministry of Health Agentura	VIAA	0,42
Lithuania	Research Council of Lithuania	LMT	0,2
Moldova	Agentia Nationala Pentru Cercetare Si Dezvoltare	ANCD	0,2

Netherlands	Zorgonderzoek Nederland Zon	ZonMw	1
Norway	Research Council of Norway	RCN	1,5
Poland	Narodowe Centrum Nauki	NCN	0,5
Spain	Agencia Estatal de Investgacion	AEI	0,6
Spain	Instituto de Salud Carlos III	ISCIII	0,5
Sweden	Swedish Research Council	SRC	30 MSEK (approx. 2,8 M€)
Sweden	Swedish International Development Cooperation Agency	Sida	3
United Kingdom	Medical Research Council	MRC	1,5
United Kingdom	Biotechnology and Biological Sciences Research Council	BBSRC	0,5
United Kingdom	Natural Environment Research Council	NERC	0,5

### 2.5 Contact persons

The only official communication line of the proposal is between the Joint Call Secretariat (JCS) (French National Research Agency, [JPI-AMRCalls@agencerecherche.fr](mailto:JPI-AMRCalls@agencerecherche.fr)) and the project coordinator. The project coordinator will be the person contacted by the Joint Call Secretariat during the application procedure, so he/she must forward this information to other participants. Each funding organisation has national contact persons who can be contacted for information about the specific national requirements (see Annex A).

Please note that country-specific requirements might apply to this call. Compliance with the national or institutional regulations specified in Annex B is mandatory. Applicants are strongly advised to contact their funding organisation (see Annex A) prior to submitting a pre-proposal.

### 3. Evaluation

International experts will perform a remote written evaluation of the proposals (minimum of two (2) experts at the pre-proposal stage and of three (3) experts at the full proposal stage). Following the remote evaluation, the international experts will meet, agree on a consensus evaluation of the proposals and recommend those that should be invited to submit a full proposal or those that should be funded depending of the evaluation stage.

Pre-proposals and full proposals will be assessed according to specific evaluation criteria (see below), using a common evaluation form.

A scoring system from zero (0) to five (5) will be used to evaluate the proposal's performance with respect to the different evaluation criteria.

#### Scoring system:

**0: Failure.** The proposal fails to address the criterion in question, or cannot be judged because of missing or incomplete information.

**1: Poor.** The proposal shows serious weaknesses in relation to the criterion in question.

**2: Fair.** The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

**3: Good.** The proposal addresses the criterion in question well but certain improvements are necessary.

**4: Very good.** The proposal addresses the criterion very well, but small improvements are possible.

**5: Excellent.** The proposal successfully addresses all aspects of the criterion in question, there are no suggestions for improvement.

**Evaluation criteria proposals:**

**1. Excellence**

Criterion	For pre-proposal	For full proposal
a. Fit to the scope of the call.	X	X
b. Clarity and pertinence of the objectives.	X	X
c. Credibility of the proposed approach and methodology, in relation to the research objectives.	X	X
d. Soundness and research base of the concept.	X	X
e. Novelty, ambition, timeliness, and innovation.	X	X
f. Excellence of the consortium with regards to competence, equity and diversity, including strength of scientific collaboration between partners, in relation to the research objectives.	X	X

**2. Impact**

Criterion	For pre-proposal	For full proposal
a. Impact of the proposal to reducing the development and transmission of antibiotic resistance.	X	X
b. Potential of the expected results for clinical, public, animal, environmental and/or other socio-economic health relevant interventions.	X	X
c. Added value of transnational collaboration and potential for fostering a longer term international network of researchers. For example, bringing together specific know-how and/or innovative technologies, gathering a critical mass of patients or biological material, sharing of resources (models, databases, biobanks, etc.), and international comparisons.	X	X
d. Potential reach of the project results, including dissemination and communication measures.	X	X
e. Potential for translation, upscaling, and use in different geographic settings, including resource-limited settings, and reflecting a One Health perspective (minimum of two One Health settings is obligatory).	X	X
f. Appropriateness of end user and stakeholder participation/engagement, for example, policy makers, industry and/or patient organisation etc.	X	X

**3. Quality and efficiency of the implementation**

Criterion	For pre-proposal	For full proposal
a. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks within the given timeframe and balanced participation of project partners (including LMIC participation if appropriate).	X	X
b. Social and gender equity, cultural sensitivity and economic viability of the project consortium and research proposal, including integrating demographic and socioeconomic factors where appropriate.	X	X
c. Quality of the proposed Open Science practices, data management and Intellectual Property management.	X	X
d. Appropriateness of the management and governance structures and procedures, including risk and innovation management.		X



e. Potential sustainability (including strategy to identify and address potential barriers) and relevance of the outcomes of the interventions beyond the current project. (long term strategy)		X
f. Contingency plan, including risk assessment and mitigation (including of unforeseen circumstances like Covid-19).		X
g. Justification of the requested budget and cost-effectiveness of the project (appropriate distribution of resources in relation to project's activities, partner responsibilities and time frame).		X

Evaluation scores will be awarded for the three main criteria, and not singularly for the different aspects listed below the criteria, although these different aspects will be taken into account in scoring the main criteria. In order for an application to be considered fundable, the threshold score for individual criteria is set at three (3) (of a maximum of five (5)). The overall threshold for the score for all three criteria together is set at nine (9). The maximum score that can be reached from all three criteria together is 15 points.

### **Ethics and legal requirements**

Proposals selected for funding will undergo an ethics review by an Ethics Panel. At the full proposal stage, in addition to the scientific content and if relevant, a full description of stakeholder engagement (or a justification if this is not applicable), safety, animal studies, genetically modified organisms and microorganisms, environmental hazards and waste handling, data management, statistical methods, ethics and legal issues will be required. Applicants should anticipate this requirement, and ensure that they have consulted with relevant experts to verify the feasibility of the project, and that the proposal can be completed within the defined budget and within the prescribed time window. In the full proposal template a self-assessment checklist will need to be completed.

Each funded consortium must have all necessary ethics approvals for research on animals, and/or research involving human subjects or data/samples obtained from human subjects according to national/regional law and regulation and in compliance with EU Horizon 2020 rules before initiation of such research. Applications for ethics approval and ethics approvals should be made available immediately to the JPIAMR JCS upon request. JPIAMR may perform an ethics review of the research at any time (evaluation and/or follow-Up of the funded projects).

Deviations from the submitted research plan affecting research under ethics approvals must be reported by the Coordinator of the project to all funding organisations involved in the project.

Any partner of a consortium in breach of research ethics regulation will subject the whole project for re-evaluation by all funding organisation of the project resulting in potential inhibition of all activities, withdrawal of funds, cancelling of contracts, and /or legal action or other sanctions according to national law.

### **Social and gender equity, cultural sensitivity and economic viability**

It is important that consortia and research proposals are founded upon principles of social and gender equity, cultural sensitivity and economic viability. Consortia are highly encouraged to apply these principles to the composition, leadership and management of research projects. Especially where LMICs are involved in the proposal, the impact to improving health and wellbeing should be considered.

Where relevant, research projects are expected to apply an intersectional and multi-dimensional approach by integrating sex, gender and other individual and population-level determinants of health (such as age, socio-economic status, ethnicity, religion, class, caste, and

other factors) into the project's design, implementation, monitoring, evaluation and knowledge translation activities.

Research projects are expected to consider individual and population-level determinants of health when collecting and analysing data to design and/or implement interventions in ways that are accessible and affordable to target beneficiaries, to systematically capture and report on sex, gender, and other relevant factors in the project research outputs, and to meaningfully engage the participation of targeted marginalised groups in the research activities.

#### **4. Decision of project to be funded**

After peer review of the pre-proposals, selected consortia will be invited by e-mail from the JCS to submit a full proposal. The final funding decision will be taken by the Call Steering Group based on the review and the recommendation by the Peer Review Panel, and will be subject to budgetary considerations and the ethical review.

#### **5. Reporting requirements and other obligations of JPIAMR grantees**

Overall project monitoring will be the responsibility of the JPIAMR secretariat. Each consortium coordinator, on behalf of the research consortium, shall submit a mid-term research project report, as well as a final research project report including a brief financial report to the JPIAMR secretariat at the end of the project. The monitoring of each funded project may also be done in review seminars. The monitoring outcomes will be collected and made accessible to all parties.

In addition to these central reporting obligations, each research team will be requested to comply with the reporting rules of its funding organisation. In accordance with those specific national/regional or institutional regulations, each participant may also be required to submit periodical and final financial and research reports to their funding organisations (See Country-specific information in Annex B).

#### **6. Intellectual Property**

The ultimate goal of Joint Programming is to bring together national research efforts in order to make better use of public R&D resources and to tackle common global challenges more effectively in selected key areas.

In order for Joint Programming activities to contribute effectively to socioeconomic growth, the results of the research activities must be exploited. This requires appropriate identification and protection of the intellectual property being generated and effective knowledge transfer. Any particular protection and exploitation strategy should be agreed before the research activities start. The ten principles of [Socially Responsible Licensing](#) (SRL) should be part of this strategy.

Depending on the nature of the research and on the interests of the different parties, if there are opportunities for exploitation, it is recommended that parties decide in advance on either adopting a common exploitation strategy or leaving exploitation of results to the party best placed to commercialise it, with appropriate compensation mechanisms for the contributing parties. National rules and regulations may apply, please consult Annex B.

#### **7. Consortium Agreement**

The consortium partners of each funded project are required to set up and sign a consortium agreement (CA) in order to deal with a.o. issues related to the role, tasks and responsibilities within the consortium, the protection of intellectual property, and where applicable how the

consortium will address the ten principles of [SRL](#). The CA needs to be in accordance with the national funding rules of the respective funding organisations, see Annex B. Make sure to verify if and when a signed copy of the CA, or a declaration hereof, needs to be sent to the respective funding organisations.

The CA must address (as a minimum), the following points:

- common start date and duration of the research project;
- organisation and management of the project;
- role, tasks, and responsibilities of each partner;
- the resources and funding;
- confidentiality and publishing;
- Intellectual Property Rights (if applicable);
- how the ten principles of Socially Responsible Licensing will be addressed (if applicable);
- decision making within the consortium;
- handling of internal disputes;
- the liabilities of the research partners towards one another (including the handling of default of contract).

Any issues regarding funding are a bilateral matter between each project partner and the relevant funding organisation and should be excluded from the CA. The CA together with any other information required by national/regional regulations must be made available on request to the national funding organisations.

Please see the [DESCA website](#) for further information on the development of a simplified consortium agreement under the Horizon 2020 Framework.

## **8. Open access and FAIR data**

Following the ambitions of open science, researchers involved in JPIAMR funded projects must ensure that science and society can be made aware of the information about the project as early as possible in the research process.

In cases where there is information that cannot be shared (either by open access publication, or by sharing of data or biological materials), this must be explained, and substantiated in the reporting template (e.g, temporary confidentiality may be accepted in the case of commercial exploitation).

### Publications (open access):

Unless it goes against their legitimate interests, each beneficiary must — as soon as possible — ‘disseminate’ its results by disclosing them to the public by appropriate means (other than those resulting from protecting or exploiting the results), including in scientific publications (in any medium).

The JPIAMR promotes Green and Gold Open Access measures, as recommended by the EC Recommendation on Open Access policies for Member States (17<sup>th</sup> July 2012), towards Horizon 2020. Each participant may also be required to comply with the Open Access policy of its funding organisation (See country-specific information in Annex B).

In the context of the JPIAMR, the following policy applies:

- Publishing costs in an open access context, related to scientific results obtained in the context of a JPIAMR project, should, in principle, be considered eligible. National funding regulations may apply (see country-specific requirements in Annex B).

- Authors are encouraged to retain their copyright or, in case of transfer of copyright to third parties, at least to retain the right to disseminate via open access. National funding regulations may apply (see country-specific requirements in Annex B).

#### Research data (FAIR):

JPIAMR requires grant holders to make their data as much as possible Findable, Accessible, Interoperable, and Reusable (FAIR). FAIR data may also be open data, however, restricted access to FAIR data is also possible. FAIR data allow researchers to verify research results and reuse data in future research. FAIR research data can typically be accessed, mined, exploited, reproduced and disseminated: under certain conditions, or free of charge for the user (=open). Also biological materials (biospecimens, microbial strains/samples, molecular derivatives) need to be FAIR. This may be done by describing the biomaterials with metadata (and these are digital).

In the context of the JPIAMR, the following policy applies:

- JPIAMR expects researchers to create reusable research data and biological materials, and to maximize the opportunities to make the research data generated from their scientific work available.
- In case that data originates from ongoing projects, the funding conditions related to those projects needs to be taken into account. These conditions cannot be overruled by conditions for new projects.
- At the end of your project, you need to provide information on how the data and/or biological materials can be found (e.g. catalogue), where they are stored (repository), the conditions for access or use to the resources (e.g. open or restricted access).

What do you need to do in the application phase?

- Check the requirements for data management and data sharing of your national funder;
- Plan the collection of research data, and biomaterials. Start planning a DMP (data management plan); consult a data expert; look for services from research infrastructures.
- Search for reusable data and biomaterials; ask for permission to use these.
- Take costs for data management and infrastructure into account when planning your budget.

Further information can be found at:

The website of JPIAMR with information about research infrastructures and the actions to create FAIR research data and biological materials (<https://www.jpiaamr.eu/infrastructure-platforms/>, <https://www.jpiaamr.eu/activities/research-infrastructure/> and <https://www.jpiaamr.eu/jpiaamr-vri/vri-resources/>)

The Science Europe ‘Practical Guide to the International Alignment of research Data Management’ with (1) core requirements for data management, allowing funders and research institutes to align their RDM requirements and template; (2) criteria for the selection of trustworthy repositories for storing and sharing research data.

[https://www.scienceeurope.org/media/jezkhnoo/se\\_rdm\\_practical\\_guide\\_final.pdf](https://www.scienceeurope.org/media/jezkhnoo/se_rdm_practical_guide_final.pdf)

The Horizon 2020 Guidelines with indications on how researchers can comply with their responsibilities regarding research data quality, sharing and security:

‘Guidelines on Open Access to Scientific Publications and Research Data in Horizon 2020’

[http://ec.europa.eu/research/participants/data/ref/h2020/grants\\_manual/hi/oa\\_pilot/h2020-hi-oa-pilot-guide\\_en.pdf](http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-pilot-guide_en.pdf)

The BBMRI services for ethical, legal and societal issues (ELSI) <http://www.bbmri-eric.eu/services/common-service-elsi/>

### **9. General Data Protection Regulation (GDPR)**

All parties, funding organisations and project partners on the applications must comply with the European General Data Protection Regulation (2016/679).

By submitting an application to JPIAMR calls all consortium partners in the application give consent to the JPIAMR to process their personal data submitted in the application in accordance with the EU Directive on General Data Protection Regulation (EU 2016/679). The consent includes transfer of personal data to third countries (non-EU/EEA-countries).

### **10. Privacy**

Responding to a JPIAMR call for proposals, both as coordinator or partner, gives JPIAMR and associated funding organisations the right to use and store the information submitted for analysis of the call success rate, national response rate, etc. Information will only be shared between the associated funding organisations and the JPIAMR secretariat. No individual/private data will be published.

Accepting a JPIAMR grant award and associated grant contract from a national funding organisation gives JPIAMR and associated funding organisations the right to store, share, publish and analyse information on beneficiaries and consortia (rules may differ between different countries). No data will be shared with third parties or commercial entities.

### **11. Acknowledgements**

All dissemination of project results (in any form, including electronic) must include the following text: "This project received funding from [name of funding organisations, or an acknowledgment as requested by your national/regional funding organisations] under the umbrella of the JPIAMR - Joint Programming Initiative on Antimicrobial Resistance".

## Annex A: National contact persons for each party providing funding

Country	Funding org.	Contact person(s)	Email	Telephone
Argentina	CONICET	Catherina Dhooge	<a href="mailto:cdhooge@conicet.gov.ar">cdhooge@conicet.gov.ar</a> <a href="mailto:coopint@conicet.gov.ar">coopint@conicet.gov.ar</a>	+54 11 4899 5400, ext. 2781/2783
Belgium	FWO	Toon Monbaliu	<a href="mailto:eranet@fwo.be">eranet@fwo.be</a>	+32 (0)2 550 15 70
Belgium	FNRS	Florence Quist Joël Groeneveld	<a href="mailto:Florence.quist@frs-fnrs.be">Florence.quist@frs-fnrs.be</a> <a href="mailto:Joël.groeneveld@frs-fnrs.be">Joël.groeneveld@frs-fnrs.be</a>	+32 (0)2 504 93 51 +32 (0)2 504 92 70
Canada	CIHR	Edith Brochu	<a href="mailto:Edith.brochu@cihr-irsc.gc.ca">Edith.brochu@cihr-irsc.gc.ca</a>	+1 581.989.2438
Canada	IDRC	Armando Heriazon	<a href="mailto:aheriazon@idrc.ca">aheriazon@idrc.ca</a>	Canada
Denmark	ICARS	Gloria Cristina Cordoba Currea  Ghada Zoubiane	<a href="mailto:gloriac@icars-global.org">gloriac@icars-global.org</a> <a href="mailto:contact@icars-global.org">contact@icars-global.org</a>	
Denmark	IFD	Jan Mousing Martin Kyvsgaard	<a href="mailto:Jm@mousing.eu">Jm@mousing.eu</a> <a href="mailto:martin.kyvsgaard@innofond.dk">martin.kyvsgaard@innofond.dk</a>	+45 5133739 +45 61905081
Estonia	ETAg	Argo Soon Margit Suuroja	<a href="mailto:argo.soon@etag.ee">argo.soon@etag.ee</a> <a href="mailto:margit.suuroja@etag.ee">margit.suuroja@etag.ee</a>	+372 730 0372 +372 731 7360
Finland	AKA	Rita Rinnankoski Sirpa Nuotio	<a href="mailto:rita.rinnankoski@aka.fi">rita.rinnankoski@aka.fi</a> <a href="mailto:sirpa.nuotio@aka.fi">sirpa.nuotio@aka.fi</a>	+358 295 335096 +358 295 335082
France	ANR	Ingrid Pfeifer Deborah Zyss Sophie Gay	<a href="mailto:JPI-AMRCalls@agencerecherche.fr">JPI-AMRCalls@agencerecherche.fr</a>	+33 1 78 09 80 22 +33 1 73 54 81 74 +33 1 78 09 80 39
Germany	DLR	Barbara Junker Akin Akkoyun	<a href="mailto:Barbara.junker@dlr.de">Barbara.junker@dlr.de</a> <a href="mailto:Akin.akkoyun@dlr.de">Akin.akkoyun@dlr.de</a>	+49 228 3821 1274 +49 228 3821 1864
Hungary	NKFIH	Dr. Klára Horváth	<a href="mailto:klara.horvath@nkfi.gov.hu">klara.horvath@nkfi.gov.hu</a>	+36 18963748
Ireland	HRB	Kay Duggan-Walls	<a href="mailto:kdugganwalls@hrb.ie">kdugganwalls@hrb.ie</a>	353 85 8868183
Ireland	DAFM	Patrick Kelly	<a href="mailto:Pat.kelly@agriculture.gov.ie">Pat.kelly@agriculture.gov.ie</a>	+353877198319
Israel	CSO-MOH	Ronit Meyuhas Irit Allon	<a href="mailto:Ronit.meyuhas@moh.gov.il">Ronit.meyuhas@moh.gov.il</a> <a href="mailto:Irit.allon@moh.gov.il">Irit.allon@moh.gov.il</a>	+97225082159 +97225082167
Italy	FRRB	PaolaBello, Carmen De Francesco Giusi Caldieri	<a href="mailto:progetti@frrb.it">progetti@frrb.it</a>	+ 39 02 67650174
Italy	It-MoH	Maria Josè Ruiz Alvarez Monica Paganelli	<a href="mailto:mj.ruizalvarez-esterno@sanita.it">mj.ruizalvarez-esterno@sanita.it</a> <a href="mailto:m.paganelli@sanita.it">m.paganelli@sanita.it</a>	+39 06 5994 3214
Latvia	VIAA	Dr Uldis Berkis	<a href="mailto:Uldis.Berkis@viaa.gov.lv">Uldis.Berkis@viaa.gov.lv</a>	+371-29472349
Lithuania	LMT	Živilė Ruželė	<a href="mailto:Zivile.ruzele@lmt.lt">Zivile.ruzele@lmt.lt</a>	+37067614383

Moldova	ANCD	Viorica Boaghi Sveatoslav Postoronca	<a href="mailto:Viorica.boaghi@ancd.gov.md">Viorica.boaghi@ancd.gov.md</a> <a href="mailto:Sveatoslav.postoronca@ancd.gov.md">Sveatoslav.postoronca@ancd.gov.md</a>	+373 22 272339 +373 22 294861
Netherlands	ZonMw	Linda van Gaalen Lisa Scheefhals	<a href="mailto:jpiamr@zonmw.nl">jpiamr@zonmw.nl</a>	+31703495157 +31703495436
Norway	RCN	Sonja Prehn Dyveke Hetland	<a href="mailto:sp@rcn.no">sp@rcn.no</a> <a href="mailto:dhe@rcn.no">dhe@rcn.no</a>	+4722037237/+4790056541 +4722037503
Poland	NCN	Monika Pobiega Jolanta Palowska	<a href="mailto:monika.pobiega@ncn.gov.pl">monika.pobiega@ncn.gov.pl</a> <a href="mailto:jolanta.palowska@ncn.gov.pl">jolanta.palowska@ncn.gov.pl</a>	+48 123419176 +48 695211478
Spain	AEI	Jesús Sanz Esther Chacón	<a href="mailto:amr@aei.gob.es">amr@aei.gob.es</a>	+34 916037105
Spain	ISCIII	Marina Moreno Cándida Sanchez Barco	<a href="mailto:marina.moreno@isciii.es">marina.moreno@isciii.es</a> <a href="mailto:cbarco@isciii.es">cbarco@isciii.es</a>	+34 918222626 +34 918222063
Sweden	SRC	Kristian Haller	<a href="mailto:Kristian.haller@vr.se">Kristian.haller@vr.se</a>	+46 8 546 12 307
Sweden	Sida	Markus Moll	<a href="mailto:Markus.Moll@sida.se">Markus.Moll@sida.se</a>	+46721434246
United Kingdom	UKRI: MRC BBSRC NERC	Jess Boname Stephen Webb Lisa Hole	<a href="mailto:Jessica.boname@mrc.ukri.org">Jessica.boname@mrc.ukri.org</a> <a href="mailto:Stephen.webb@bbsrc.ukri.org">Stephen.webb@bbsrc.ukri.org</a> <a href="mailto:Lisa.hole@nerc.ukri.org">Lisa.hole@nerc.ukri.org</a>	

## Annex B: National Rules and Requirements

Please note that this is only a summary. Refer to the national websites and contact the respective national contact persons for full details.

Argentina – CONICET Consejo Nacional de Investigaciones Cientificas y Tecnicas	
<b>Specific National/ Regional rules</b>	<p>Argentinean PI</p> <ul style="list-style-type: none"> <li>• He/She shall be working at a national S&amp;T or HE institution.</li> <li>• The project head with administrative responsibilities must be a member of the Scientifically Research Career of CONICET based on any national institution</li> <li>• Cannot simultaneously submit or participate in other proposal within this call.</li> </ul> <p>Research group:</p> <ul style="list-style-type: none"> <li>• There is no maximum of project members</li> <li>• It's highly recommended that the proposal includes the association of, at least, three (3) different research groups from different research centres in Argentina.</li> <li>• Project members are recommended to hold or participate in an ongoing national research project from CONICET or ANPCyT.</li> <li>• If half of the members are simultaneously included in other research proposal, a justification shall be provided.</li> <li>• Research projects can be integrated by members of any national institution.</li> <li>• Interested applicants should contact the CONICET contact point (see Annex A), in order to verify the eligibility of the proposals and avoid ineligible projects/research consortia.</li> </ul>
<b>Eligible costs</b>	<p>Projects may last up to 36 months.</p> <ul style="list-style-type: none"> <li>• <b>Mobility - Maximum: 60% of total budget.</b> <ul style="list-style-type: none"> <li>○ travel + accommodation to a partner country.</li> <li>○ Short-term exchange visits</li> </ul> </li> </ul> <p><i>Mobilities will be paid directly by CONICET to the beneficiary, according to its internal procedures. Detailed information will be provided to selected projects.</i></p> <p><i>Beneficiaries shall be postdoctoral fellows and/or Researchers from CONICET.</i></p> <p>Research cost and local activities: <i>Up-to 40% of total budget</i></p> <ul style="list-style-type: none"> <li>• Meeting, workshops and events organization in Argentina</li> <li>• Publication, dissemination</li> <li>• Consumables</li> <li>• Small equipment</li> <li>• Field trips in Argentina</li> </ul> <p><u>Indirect Costs:</u> Only administration</p> <p>Note: personnel cost and subcontract cost will not be covered</p> <ul style="list-style-type: none"> <li>• Clinical trials will not be funded.</li> </ul>
<b>Additional documents required</b>	<p>Applicants shall formally communicate their willingness to participate in this call to the International Cooperation Office 7 days prior to the official deadline, together with Letter of Support from the authority of their home institution. Detailed information will be provided by the contact point.</p>
<b>Eligible One Health settings</b>	<p>All three research areas (Human health, Animal health and Environmental health) are eligible for funding.</p>



<b>Conditions clinical studies (if any)</b>	Clinical trials will not be funded by CONICET
<b>Further information</b>	<b>CONICET will fund up-to four (4) Argentinean proposals with up-to €25.000 each according to its own administrative procedures.</b> Funding will be paid in local currency. Duration of projects will be of 3 years each. CONICET will pay regular salaries and stipends of its staff researchers and fellows during the project execution period.

<b>Belgium – FWO Fonds voor Wetenschappelijk onderzoek-Vlaanderen</b>	
<b>Specific National/ Regional rules</b>	<p><b><u>Involved regional Funding Programmes:</u></b> Both the FWO Strategic Basic Research Projects (SBO), next to the more fundamental junior/senior research projects (FO), are integrated in this call, each with their specific eligibility conditions. It is, in the light of the projects eligibility, of utmost importance to respect the appropriate regulations. For example when it comes to the <b><i>mandatory valorisation aspect for the SBO projects.</i></b></p> <p>It is consequently strongly advised to contact the FWO contact point (see Annex A), in order to verify the eligibility of the proposals and avoid ineligible projects/research consortia.</p> <p><b><u>Who is eligible for FWO funding?</u></b></p> <p>The eligibility of institutions and its researchers can be verified in the relevant regulations:</p> <p>→ For Fundamental research, <a href="#">see articles 10-12</a></p> <p>→ For Strategic Basic Research, <a href="#">see articles 4-8</a></p>
<b>Eligible costs</b>	<p><b><u>Minimum and/or maximum project duration:</u></b> Projects may last up to 36 months, which implies the funding has to be budgeted and spent accordingly. Extensions are not allowed in this phase.</p> <p><b><u>Minimum and/or maximum funding per project:</u></b> The maximum requested budget per partner amounts to 350.000 EUR (incl. overhead).</p> <p><b><i>Beware, the funding rules differ per FWO funding channel (FO and SBO):</i></b></p> <p>- <b>FO:</b> a 6% structural overhead should be calculated on the direct costs. E.g., a practical example: if the sum of all project costs (personnel, consumables, travel, etc.) amount to 300.000 EUR, then the overhead will amount to 18.000 EUR (6% of 300.000 EUR) and the total requested cost 318.000 EUR. This total requested cost may never exceed 350.000 EUR.</p> <p>- <b>SBO:</b> The <a href="#">SBO cost model</a> applies.</p>
<b>Additional documents required</b>	When the Flemish sub-proposal has a strategic orientation, and thus the strategic basic research channel would be the appropriate choice of funding, we ask researchers <b>to provide us with a ‘valorisation plan’ before the pre-proposal submission deadline.</b> There is no fixed format and one A4 page should suffice. What the FWO wants to know is how the valorisation within Flanders - and potentially internationally – will take place (economic and/or societal finality) and

	which Flemish actors are involved in this project. This information can be submitted to the general <a href="mailto:eranet@fwo.be">eranet@fwo.be</a> email address.
<b>Eligible One Health settings</b>	All research areas (Human health, Animal health and Environmental health) are eligible for funding.
<b>Conditions clinical studies (if any)</b>	Projects are eligible up to 'pre-clinical' research. 'Clinical' research is not eligible for researchers applying at FWO.
<b>Further information</b>	<ul style="list-style-type: none"> <li>- One and the same researcher can only participate in 2 different research projects/consortia when applying for FWO funding, within the same call. Double funding is not allowed.</li> <li>- Researchers have to inform their central research coordination units, at their host institutions, about their participation.</li> </ul>

<b>Belgium – FNRS Fonds de la Recherche Scientifique</b>	
<b>Specific National/ Regional rules</b>	<ul style="list-style-type: none"> <li>• All eligibility rules and criteria can be found in the <a href="#">PINT-Multi regulations</a></li> </ul>
<b>Eligible costs</b>	<p><b>The maximum requested budget is 200.000 € per project for 3 years</b></p> <ul style="list-style-type: none"> <li>• All eligibility rules and criteria can be found in the <a href="#">PINT-MULTI regulations</a></li> <li>• <b>“Overhead” is not an eligible cost.</b> If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS.</li> </ul>
<b>Additional documents required</b>	<p><b>Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on <a href="#">e-space</a> within 5 working days after the general deadline of JPIAMR action to be eligible. Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS.</b></p>
<b>Eligible One Health settings</b>	All 3 research areas (Human Health, Animal Health and Environement) are eligible for funding.
<b>Conditions clinical studies (if any)</b>	Clinical studies are <b>not</b> eligible for funding by the F.R.S.-FNRS
<b>Further information</b>	<p>Additional national eligibility criteria for the proposal beyond the general criteria of the joint call</p> <ul style="list-style-type: none"> <li>• Basic research (low Technology Readiness Level) carried out in a research institution from the “Fédération Wallonie-Bruxelles”</li> <li>• The F.R.S.-FNRS will not fund clinical research</li> <li>• The F.R.S.-FNRS will not fund industrial partners or any activity related to the private sector</li> </ul>

<b>Canada – CIHR Canadian Institutes of Health Research</b>	
<b>Specific National/ Regional rules</b>	<ul style="list-style-type: none"> <li>• Categories of individuals eligible to apply for CIHR grants include, but are not limited to, researchers, knowledge users, scholars, health professionals, undergraduates, graduate students, and postdoctoral scholars.</li> <li>• Among eligible organisations that CIHR may fund are non-governmental organisations with a research or knowledge translation mandate. Details regarding eligible applicants for a given competition will be specified in the funding opportunity on <a href="#">ResearchNet</a>.</li> <li>• Individuals in the Nominated Principal Applicant role must be affiliated with a Canadian postsecondary institution and/or their affiliated institutions;</li> </ul>

	<p>individuals working with municipal, provincial, and/or territorial governments are also eligible where the research proposed is not already funded by that Government of Canada sector.</p> <ul style="list-style-type: none"> <li>• Individuals in the Nominated Principal Applicant role must have their substantive role in Canada for the duration of the requested grant term.</li> <li>• Appointments and/or positions that can be renewed prior to the end of the requested grant term are eligible at the discretion of the administering institution.</li> <li>• CIHR grants and awards are paid to <a href="#">CIHR-eligible institutions</a>, through a CIHR account, from which the Nominated Principal Applicant draws funds.</li> <li>• Canadian applicants must complete a CIHR application and submit it using <a href="#">ResearchNet</a> in addition to the proposal submitted to the <a href="#">Joint Call Secretariat</a>.</li> <li>• Canadian applicants must submit an Operating Budget for the project, with the amounts quoted in <b>Canadian dollars</b>, and a complete justification for funds requested using <a href="#">ResearchNet</a> in addition to the proposal submitted to the <a href="#">Joint Call Secretariat</a>. The deadline for submission of this application is the same as the proposal deadline to the Joint Call Secretariat.</li> <li>• Projects receiving a CIHR grant must comply fully with the <a href="#">CIHR Funding Policies</a>. Policies and guidelines cover areas such as Applicant Responsibilities, Official Languages policy, Access to Information and Privacy Acts.</li> </ul>
<p><b>Eligible costs</b></p>	<ul style="list-style-type: none"> <li>• Applicants should review the Use of Grant Funds Section of the Tri-Agency (CIHR, NSERC and SSHRC) <a href="#">Guide on Financial Administration</a> for a complete listing and description of allowable costs and activities.</li> </ul> <p>The costs for data management, infrastructure, data storage and data sharing is considered an eligible expense.</p>
<p><b>Additional documents required</b></p>	<ul style="list-style-type: none"> <li>• Applications submitted to CIHR require applicant consent and institutional approval (if applicable) to the use and disclosure of full application and nominative information for relevance review and funding decisions at the time of application.</li> <li>• The applicant will be required to submit to all JPIAMR reporting requirements.</li> <li>• The Nominated Principal Applicant will be required to submit an Electronic Final Report to CIHR. This online report will be made available to the Nominated Principal Applicant on <a href="#">ResearchNet</a> at the beginning of the grant funding period and can be filled in as the research progresses.</li> <li>• All reports may be shared with partners supporting the grant.</li> <li>• The Nominated Principal Applicant must have successfully completed one of the <a href="#">sex- and gender-based analysis training modules</a> available online through the CIHR Institute of Gender and Health and have submitted a Certificate of Completion (see <a href="#">How to Apply</a> section). Select and complete the training module most applicable to your research project. Applicants are encouraged to review the "<a href="#">How to integrate sex and gender in research</a>" section on the CIHR website.</li> </ul> <p>CIHR is committed to promoting the inclusion and advancement of groups underrepresented in science as one of the means to enhance excellence in research, training and knowledge translation. CIHR's position on equity, diversity and inclusion (EDI) is available in the <a href="#">Tri Agency Statement on Equity, Diversity and Inclusion</a>. Additional guidance can be found on the <a href="#">Best practices in Equity, Diversity and Inclusion in Research</a> webpage.</p> <p>Consortium Agreement</p> <ul style="list-style-type: none"> <li>• It is incumbent upon the Canadian researchers to review and understand all expectations of the JPIAMR 13<sup>th</sup> call text available including the requirement for a <a href="#">Consortium Agreement (CA)</a>. The Consortium Agreement</li> </ul>

	<p>specifies the relationship among the funded researchers, outlines how the project will be organized and managed and includes clauses related to Intellectual Property and FAIR data.</p> <ul style="list-style-type: none"> <li>The Nominated Principal Applicants who are successful in this competition will be expected to develop and sign a <a href="#">Consortium Agreement (CA)</a> - depending on the composed consortium, different rules are applicable. Please consult the relevant country National rules and requirement in this Annex and discuss with your consortium partners when a signed CA is required and plan ahead*.</li> <li>NPA do NOT need to send a signed copy of the CA, nor a declaration of the CA to CIHR. JPIAMR will contact you directly for a copy should it be needed.</li> </ul> <p><b>* It is noted that CIHR does not retain or claim any rights to IP in relation to research that it funds. Accordingly, the Canadian researchers retain full freedom in negotiating the Consortium Agreement required, including whether or not to accept the IP conditions.</b></p>
<b>Eligible One Health settings</b>	Projects addressing a minimum of two (2) One Health areas with one of them being Human Health related will be eligible.
<b>Conditions clinical studies (if any)</b>	<ul style="list-style-type: none"> <li>Projects involving clinical studies will be accepted under this Funding Opportunity.</li> </ul> <p>Projects receiving a CIHR grant and any other persons working on the project must fully comply with the applicable <a href="#">CIHR Funding Policies</a>.</p>
<b>Further information</b>	<p>The total amount available for the Canadian component of successful projects is 2.2 million CAD \$, enough to fund the Canadian component of approximately up to four (4) joint transnational teams. The proposals will be funded based on the ranking list recommended by the PRP and decided by the CSG. The final funding decision will be made by the national/regional funding organisations and will be subject to budgetary considerations with the goal of optimal usage of the available budget. CIHR funds will be awarded and distributed based upon the nature of Canadian participation on the funded application as follows:</p> <ul style="list-style-type: none"> <li>Canadian Nominated Principal Applicant – leading the joint transnational team (i.e Coordinator of the consortium) up to 200,000 CAD \$ per year for three (3) years for a maximum of 600,000 CAD \$ <b>for the Canadian component of the joint transnational team</b></li> <li>Canadian Nominated Principal Applicant - participating in the joint transnational team (i.e Partner in the consortium) up to 166,667 CAD\$ per year for three (3) years for a maximum of 500,000 CAD \$ <b>for the Canadian component of the joint transnational team</b></li> </ul> <p>Above amounts are NOT cumulative in the situation where more than one Canadian investigators are involved in a given project. For example, total funding for a project involving one (1) Canadian Coordinator and one (1) Canadian Partner or more cannot exceed 600,00 CAD \$ per grant over three (3) years. Similarly, total funding for a project involving two (2) Canadian Partners or more cannot exceed 500,000 CAD \$ per grant over three (3) years.</p> <p>Approved joint transnational teams may receive an across-the-board cut to the budget, if necessary, to maximize the number of funded opportunities.</p> <p>For full details of CIHR’s requirements, please refer to the Funding Opportunity on <a href="#">ResearchNet</a>.</p>

**Canada – IDRC  
International Development Research Centre**

<b>Specific National/ Regional rules</b>	<p>IDRC will contribute up to CAD 1 million to support research consortia which involve the participation of researchers from low and middle-income countries in Southeast Asia and which meet the following criteria:</p> <ul style="list-style-type: none"> <li>• Only researchers based in Southeast Asian countries listed on the 2020 DAC List of ODA Recipients<sup>9</sup> are eligible to receive IDRC funding.</li> <li>• Only researchers in eligible organizations are eligible to receive IDRC funding. Eligible organizations are legal entities, such as accredited universities, non-governmental or government-funded research organizations.</li> <li>• Researchers from intergovernmental organizations (e.g. United Nations system) and CGIAR Centres may serve as collaborators in an IDRC-funded consortium but are not eligible to receive IDRC funding themselves.</li> <li>• IDRC funded researchers and research institutions may negotiate and develop funding arrangements directly with third-party organizations for specific services. IDRC will not contract directly with third-party organizations. Applications that involve third-party organizations must clearly justify their involvement and explain their role(s).</li> </ul> <p>Grant agreements with eligible and successful projects will be made directly with IDRC and the associated technical and financial reporting must follow IDRC guidelines in the grant agreement.</p>
<b>Eligible costs</b>	<p><a href="#">Guidelines for Acceptable Project Expenditures Proposal Budget</a></p>
<b>Additional documents required</b>	<p><a href="#">Institutional Profile Questionnaire</a> Ethical clearance (may be submitted after approval of the project) Country clearance (if required)</p>
<b>Eligible One Health settings</b>	<p>Human health, animal health, crop health, environmental health. Projects not showing gender sensitivity are not eligible.</p>
<b>Conditions clinical studies (if any)</b>	<p>Projects purely involving clinical studies are not eligible for IDRC funding. Project focused purely in diagnostics are not eligible. Projects at the stages of discovery and applied research are eligible.</p>
<b>Further information</b>	<p><u>Budget of research grants</u> Eligible research consortia applying for IDRC funding may request a budget between \$300,000 - 500,000 CAD to support the participation of eligible South East Asian researchers.</p> <p>Consortia with a total LMIC research budget greater than \$500,000 CAD are eligible, however applicants will be expected to provide a strong rationale (such as the added-value of a multi-country or multi-institutional collaboration) that justifies this larger budget.</p> <p><u>Country agreements</u> IDRC has conducted general agreements for scientific and technical cooperation with a number of governments. As such, the applicant institution may be required to obtain approval from the host country in accordance with these agreements prior to receiving funding from IDRC. This requirement applies only for selected applications. For eligible projects that are recommended by the Peer Review Panel, IDRC will consider the administrative requirements and the time expected to follow these country agreements. IDRC reserves the right to not pursue the funding of a project if there is a reasonable risk that these</p>

<sup>9</sup> <http://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/DAC-List-of-ODA-Recipients-for-reporting-2020-flows.pdf>

	<p>administrative requirements will jeopardize the timely completion of this JPIAMR-ACTION Call.</p> <p><a href="#">General IDRC Funding Guidelines</a>  <a href="#">Grants to Institutions: A Guide to Administrative Procedures</a>  <a href="#">Grants to Institutions: Frequently Asked Questions</a>  <a href="#">Standard Terms and Conditions for a Grant Agreement</a></p>
--	--

Denmark – ICARS International Centre for Antimicrobial Resistance Solutions	
<b>Specific National/ Regional rules</b>	<p>ICARS is a One Health intervention and implementation research partnership, initiated by Denmark, with a mission to support low- and middle-income countries (LMICs) in their efforts to mitigate AMR. Specifically, ICARS will partner with LMICs to develop evidence-based, context-specific and cost-effective solutions to AMR. Doing so, ICARS will support LMICs in implementing aspects of their AMR National Action Plans, as well as contribute to closing the existing knowledge gap on what solutions work nationally and locally, and how policy can be translated into practice</p> <p>Proposals eligible for ICARS funding will need to demonstrate strong collaboration and partnership with their relevant ministries, and articulate how their proposal can help deliver on the countries National Action Plans.  <b><u>Letters of support from the relevant ministries will be required as part of the full proposal stage.</u></b></p> <p><b>Eligibility:</b>  ICARS will support the participation of researchers from LMICs belonging to the ‘DAC’ list (The updated list can be accessed on <a href="#">OECD's webpage</a>).</p> <p><b>Institutions:</b> Eligible to apply are universities or other research institutions (public and private) and non-profit organizations based in LMICs. Profit making organisations are not eligible to lead and receive ICARS funding, but can join in as part of the consortium.</p> <p><b>Applicants:</b> Eligible to apply are researchers employed by domestic universities or other research institutions, including non-profit organizations, in LMICs. Researchers from profit making organisations are not eligible to lead, but can join as part of the consortium.</p> <p>Researchers may only be listed as a project coordinator on <u>one</u> project application but can join other consortia as a partner.</p> <p><u>Potential applicants are strongly advised to contact ICARS secretariat as detailed in Annex A of the Call in advance of making an application to resolve any eligibility queries.</u></p> <p>As part of this call, ICARS will be working closely with other LMIC funders (IDRC and SIDA) to support engagement by LMIC partners.</p>
<b>Eligible costs</b>	<p>Subject to eligibility and review, ICARS aims to provide € 1.0 million for this call.</p> <p>We anticipate a total maximum requested <b>€500.000 per consortium</b> (across eligible partners) and up to <b>€300.000 per partner</b> (including overhead).</p>

	<p>Eligible costs include project related cost incurred after the award start date such as staff and investigator costs (salaries), tuition fees/educational grants (where relevant), consumables, travel (including fieldwork), research equipment and materials, workshops and meetings, publications, dissemination, outreach and overhead costs.</p> <p>PhD students based in LMICs are eligible to be included when applying for ICARS funding.</p> <p>No grantee is permitted to make sub-grants, but all grantees will be permitted to contract for services, up to a maximum of 20,000 Euro.</p> <p>Overhead is calculated as a fixed percentage of direct costs. Institutions eligible to receive overhead are research institutions, universities and non-profit organisations based in LMICs. The maximum overhead rate is 15 %, but if a research institution, university or non-profit organisation has an actual overhead/indirect cost rate that is lower than the maximum rate, the lower rate will apply and the research institution/university/non-profit organisation may <i>not</i> increase the funding request to the maximum overhead rate allowed. Research institutions, universities and non-profit organisations are required to provide documentation if they have a general overhead/indirect cost rate.</p>
<b>Additional documents required</b>	<p>When submitting their full proposals, applicants will be requested to submit letter(s) of support from their relevant LMIC ministries, articulating how the relevant research will advance NAP implementation. More guidance can be provided by the ICARS contact in Appendix A.</p> <p>Successful proposals will be requested to submit their application to ICARS within one month from the date they are notified of a positive funding decision.</p>
<b>Eligible One Health settings</b>	All One Health settings including humans, animals, plants, and the environment are eligible for ICARS funding
<b>Conditions clinical studies (if any)</b>	No additional conditions other than what is described in the call.
<b>Further information</b>	<p>Individuals that are members of projects invited to make a full proposal may be required to submit additional information that pertains to their specific work and/or budget within the research consortium to ICARS, or a designated partner organization.</p> <p>Awardees supported by ICARS will need to comply with ICARS policies including Data sharing, Open access and Intellectual properties. Awardees will be expected to provide an annual progress report and annual accounts.</p>

<b>Denmark – IFD Innovationsfonden</b>	
<b>Specific National/Regional rules</b>	<b>Institutions eligible for funding:</b> SME's, Large Enterprises, GTS, Universities & University Colleges, Public Hospitals, Other public institutions

Activity typology	Applicant typology		Investment rates for Innovation Fund Denmark					
			Actual costs Salary max 1.000 DKK per hour		Actual costs X institute rate	Public organisations		
			SME's	Large Enterprises	GTS	Universities & University Colleges	Public Hospitals	Other public organisations
Industrial Research	Grant	75%	65%	60%	90% + 44% overhead	90% + 3,1% overhead	90% - no overhead	
Experimental Development	Grant	33%	25%	60%	90% + 44% overhead	90% + 3,1% overhead	90% - no overhead	
<b>Eligible costs</b>	Eligible cost-categories are: Salary, Travel, Subcontracting, Materials, Communication and knowledge sharing and 'Other expenses'.							
	Available budget: € 1.0 mio. Total maximum requested is €500.000 per project and €300.000 per partner (including overhead).							
<b>Additional documents required</b>	<b>Registration of applications for Danish partners in International Projects:</b> All Danish partners in International Project applications under IFD must register in our online administration platform E-grant. The deadline for the registration is two weeks after the deadline for submitting the project application. Register under the same call option as you have applied. Name your project [Application ID – Acronym – Institution/Company].							
<b>Eligible One Health settings</b>	Human, animal, and environment.							
<b>Conditions clinical studies (if any)</b>	None.							
<b>Further information</b>	<b>Guidelines for Danish participants in international projects:</b> <a href="https://innovationsfonden.dk/sites/default/files/2018-10/general-terms-and-conditions-for-international-projects-approved-after-1-feb-2018.pdf">https://innovationsfonden.dk/sites/default/files/2018-10/general-terms-and-conditions-for-international-projects-approved-after-1-feb-2018.pdf</a>							

Estonia – ETAg Estonian Research Council	
<b>Specific National/Regional rules</b>	Any legal body established in Estonia can be funded if the research team accords to requirements (see link below)
<b>Eligible costs</b>	All research related costs will be covered. Maximum grant size is 100 000 euros.
<b>Additional documents required</b>	None.
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Conditions clinical studies (if any)</b>	Phase I and II is eligible.
<b>Further information</b>	<a href="https://www.etag.ee/wp-content/uploads/2020/03/Vastavusno%CC%83uded- RV- u%CC%88hiskonkurssidel_kinnitatud-12.03.2020.pdf">https://www.etag.ee/wp-content/uploads/2020/03/Vastavusno%CC%83uded- RV- u%CC%88hiskonkurssidel_kinnitatud-12.03.2020.pdf</a>

Finland – AKA Academy of Finland	
<b>Specific National/Regional rules</b>	The funding will follow guidelines of the Academy Project funding. See further instructions in <a href="#">General conditions and guidelines for funding</a> . The applicant must have the qualifications of a professor or a docent.



<b>Eligible costs</b>	Full cost model applies; both direct and indirect costs of the research team arising from salaries, consumables, travel, mobility, overheads etc. Requested budget from the Academy must be no more than 70% of the full costs of a Finnish PI.  Available budget: 0,6M for 2 projects.
<b>Additional documents required</b>	Data management plan. A researcher who has received a positive funding decision must submit the actual data management plan within eight weeks of the funding decision.
<b>Eligible One Health settings</b>	All three research areas (Human health, Animal health and Environmental health) are eligible for funding.
<b>Conditions clinical studies (if any)</b>	Both pre-clinical and clinical studies are welcome.
<b>Further information</b>	The Finnish project leaders recommended for funding will be invited to submit an application to the Academy of Finland in autumn 2021.

<b>France – ANR French National Research Agency</b>	
<b>Specific National/ Regional rules</b>	ANR may finance fundamental research, industrial research and experimental developments. Funded Partners must have their primary establishment in France and/or in the EU with a secondary establishment in France. Within this framework, research institutions such as EPST, EPIC, Universities, Hospitals as well as most foundations and Enterprises can apply. <u>This list is not comprehensive and funding rates vary</u> . Please fill the <u>form related to economical activities</u> to identify your funding rate and <u>consult the “règlement financier”</u> <a href="http://www.agence-nationale-recherche.fr/RF">http://www.agence-nationale-recherche.fr/RF</a> for more details. Please note that companies with <u>economic difficulties</u> are excluded from ANR subventions.
<b>Eligible costs</b>	Standard ANR funding rules apply for eligible costs. These rules are specified in ANR’s <u>“Règlement financier”</u> mentioned above and in an explanatory note available at: <a href="https://anr.fr/fileadmin/documents/2017/ANR-RF-Fiche-COUTS.pdf">https://anr.fr/fileadmin/documents/2017/ANR-RF-Fiche-COUTS.pdf</a>  Eligible costs (e.g.: personnel costs of non-permanent researchers, costs of instruments and equipment, additional overheads and other operating expenses incurred directly as a result of the research project such as, for instance: travel costs) and funding rates vary based on the type of research and research partner. Please note that expenses related to permanent staff are not eligible for the beneficiaries “à coût marginal”.
<b>Additional documents required</b>	No additional documents should be submitted to ANR during the submission phase. If a project is selected for funding, French partners will have to fill administrative and financial data on the ANR platform.
<b>Eligible One Health settings</b>	All 3 research areas (Human Health, Animal Health and Environnement) are eligible for funding.
<b>Conditions clinical studies (if any)</b>	Pre-Clinical or clinical studies are not eligible for funding but research proposals based on results previously obtained through clinical studies are welcome.
<b>Further information</b>	<b>Maximum amount per project:</b> 470 000 € <b>Maximum funding per partner:</b> 260 000 € (Increased to 310 000 € for coordinators) <b>Minimum amount per partner:</b> 15 000 €  More details for the participation of French partners ( <i>“Modalités de participation”</i> ) at <a href="https://anr.fr/fileadmin/aap/2020/aap-jpiamr-action-2021-">https://anr.fr/fileadmin/aap/2020/aap-jpiamr-action-2021-</a>

	modalités -fr.pdf. In case of a conflict of interpretation between the terms and conditions stated in this annex and the “ <i>Modalités de participation</i> ” and “ <i>Règlement financier</i> ”, the terms of the latter shall prevail.
--	---

<b>Germany – DLR Deutsches Zentrum fuer Luft – und Raumfahrt Ev</b>	
<b>Specific National/ Regional rules</b>	Legal bodies: <ul style="list-style-type: none"> <li>• Universities</li> <li>• University hospitals</li> <li>• Non-university research institutes</li> <li>• Industry</li> </ul> Note: industry is funded with a maximum of 50-60% of their costs.
<b>Eligible costs</b>	Personnel, Consumables, Animals, Subcontracts, Equipment, Travel, Overheads refer to “Gemeinkosten” (applicable e.g. for Helmholtzcentres and Fraunhofer-Society) as well as “Projektpauschale” (applicable for universities and university hospitals). Individual project coordinators/partners may request up to 300 000 Euro. A project consisting of two or more German partners may request a maximum of 500 000 Euro. For further details please refer to the national guidelines “ <u>BMBF Formularschrank</u> ” <sup>1</sup>
<b>Additional documents required</b>	no
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Conditions clinical studies (if any)</b>	Phase I and II is eligible.
<b>Further information</b>	For further details please refer to the national guidelines “ <u>BMBF Formularschrank</u> ” <sup>1</sup>

1

[https://foerderportal.bund.de/easy/easy\\_index.php?auswahl=easy\\_formulare&formularschrank=bmbf#t1](https://foerderportal.bund.de/easy/easy_index.php?auswahl=easy_formulare&formularschrank=bmbf#t1)

<b>Hungary – NKFIH National Research, Development and Innovation Office</b>	
<b>Specific National/ Regional rules</b>	Eligible applicants from Hungary are entities falling under any of the following GFO codes: <ul style="list-style-type: none"> <li>• enterprise with legal entity (GFO code: 11X)</li> <li>• non-profit organisation with legal entity (GFO code: 5XX)</li> <li>• budgetary units and entities (eg. higher education institutions, municipalities;) (GFO code: 3XX)</li> <li>• enterprise</li> </ul>
<b>Eligible costs</b>	All research-related costs in accordance with government decree 380/2014 (XII.31) are eligible. In case a partner is subject to State Aid rules, funding intensity shall be set at a level that complies with the State Aid rules in force at the time of the funding decision (The Guide for Applicants for the 2019-2.1.7-ERA-NET national call is applicable.)
<b>Additional documents required</b>	
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.

<b>Conditions clinical studies (if any)</b>	
<b>Further information</b>	<a href="https://nkfi.gov.hu/palyazoknak/nkfi-alap/era-net-ejp-cofund-2019-217-era-net/palyazati-felhivas-2019-217-era-net">https://nkfi.gov.hu/palyazoknak/nkfi-alap/era-net-ejp-cofund-2019-217-era-net/palyazati-felhivas-2019-217-era-net</a>

<b>Ireland – HRB</b> <u>The Health Research Board</u>	
<b>Specific National/ Regional rules</b>	<ul style="list-style-type: none"> <li>• The Lead Applicant (PI, Irish Partner) must be affiliated with a HRB host institution (<a href="#">Policy on Approval of HRB Host Institutions</a>). See additional criteria for Lead Applicants in the HRB Guidance Notes for this call <a href="#">HRB Funding Schemes</a></li> <li>• Proposals must include human as one of the One Health settings;</li> <li>• Proposals addressing the following <u>are eligible</u>: <ul style="list-style-type: none"> <li>○ Understand the impact of interventions on the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings</li> </ul> </li> <li>• Proposals addressing the following <u>are not eligible</u>: <ul style="list-style-type: none"> <li>○ Design, implement, evaluate, and/or compare innovative interventions to control the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings;</li> </ul> </li> <li>• The maximum funding from the HRB is €370,000 for up to 3 years.</li> <li>• Proposals from Irish partners that include human Embryonic Stem Cell Research will be deemed ineligible</li> </ul>
<b>Eligible costs</b>	<p>Funding available is inclusive of overheads and pension contributions</p> <ul style="list-style-type: none"> <li>• Personnel <ul style="list-style-type: none"> <li>○ Salary-related costs for research personnel</li> <li>○ Stipends and fees (EU only)</li> </ul> </li> <li>• Small equipment costs</li> <li>• Travel costs</li> <li>• Direct running costs</li> <li>• FAIR data management costs</li> <li>• Dissemination and knowledge exchange costs</li> <li>• Overheads contribution</li> </ul>
<b>Additional documents required</b>	<p>Irish Partners in consortia invited to submit a full proposal will be requested to provide the following documents to the HRB National contact person at the time of the full proposal submission deadline.</p> <ul style="list-style-type: none"> <li>• Supplementary budget Information with justification</li> <li>• Clarification on deliverables assigned to the Irish partner</li> </ul> <p>A template requesting the information will be provided by the HRB.</p> <p>Additional guidance notes with national rules can be found on the HRB funding page, <a href="#">HRB Funding Schemes</a></p>
<b>Eligible One Health settings</b>	<p>It is a requirement for HRB applicants to include Human Health as one of the One Health Settings.</p> <p>Irish applicants planning an application covering animal and human health are advised to consult with both Irish Funders (HRB and DAFM) to discuss eligibility requirements for funding prior to application.</p>
<b>Conditions clinical studies (if any)</b>	<p>Proposals addressing the second bullet point under the scope of the call:</p>

	<ul style="list-style-type: none"> <li>Design, implement, evaluate, and/or compare innovative interventions to control the development and transmission of antibiotic resistance in, and/or or between, at least two One Health settings.</li> </ul> <p>are <u>not eligible</u> to apply for HRB funding</p>
<b>Further information</b>	Maximum funding <b>370,000 EUR</b> (inclusive of overheads and pension contributions) in total over <b>36 months</b> . It is expected that one or two awards will be awarded depending on the funding requested from applications with Irish partner(s).

<b>Ireland – DAFM Department of Agriculture, Food and the Marine</b>	
<b>Specific National/ Regional rules</b>	<p><b>National eligibility criteria:</b></p> <ol style="list-style-type: none"> <li>Grant applications will only be accepted from DAFM approved Irish RPOs</li> <li>The grant request by Irish RPOs must not exceed the maximum funding per project as set out in the relevant Guidelines for Irish Applicants</li> <li>Address at least one of the JPIAMR-ACTION's Call's scientific topic areas (as set out in the central JPIAMR-ACTION Call announcement)</li> <li>Avoid duplication of recent research work already undertaken or ongoing that incorporates the scope of the scientific topic areas in the JPIAMR-ACTION Call</li> <li>Closely align with applicable Strategic Research and Innovation Agenda priority areas</li> <li>Align with relevant national policy and foresight documents..</li> </ol> <p>Applications that do not adhere to these criteria <b>will be deemed ineligible</b> and in such cases the application will not proceed for expert review.</p>
<b>Eligible costs</b>	Eligible costs will be allowed in the categories of: <ol style="list-style-type: none"> <li>Staff Costs</li> <li>Equipment</li> <li>Travel and Subsistence (T&amp;S)</li> <li>Consumables</li> <li>Overheads</li> <li>Other agreed costs e.g. Sub-Contracting</li> </ol>
<b>Additional documents required</b>	Guidelines for Applicants' located on the DAFM website which sets out in more detail the rules for Irish applicants seeking grant-aid and which must be read in conjunction with the requirements set out in the National Annex.
<b>Eligible One Health settings</b>	Animal health, environmental health.
<b>Conditions clinical studies (if any)</b>	Standard National Grant Conditions apply.
<b>Further information</b>	

<b>Israel – CSO-MOH Chief Scientist Office, Ministry of Health</b>	
<b>Specific National/ Regional rules</b>	<p>CSO-MOH (Israel) will only fund proposals with relation to Human Health. PI should hold a Ph.D., M.D., D.M.D., D. Sc or equivalent degree and employed by an eligible institution ( hospitals, clinics, laboratories, academic and public research institutions</p> <p>Research will not be funded simultaneously by CSO-MOH on more than one grant (Era-NET or national). Researchers can not apply for more than one grant from any ERA-NET funded by CSO-MOH or submit more than one proposal for any programme.</p>

<b>Eligible costs</b>	Materials and consumables; Travel (up to 10%); No salaries for applicants; No heavy equipment, Institutional overhead 10%.  Available budget: 0.3M (up to 2 projects. 140K per project + additional 20K per project coordinators)
<b>Additional documents required</b>	Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of abstract can result in declaration of the consortium as ineligible. If the application involves human or animal experiments, bioethics approvals must be submitted with the application or up to 4 months later.
<b>Eligible One Health settings</b>	Human health, Animal health, Environmental health (Only in relation to human health).
<b>Conditions clinical studies (if any)</b>	Standard National Grant Conditions apply
<b>Further information</b>	Please see detailed instructions of application at the national level and reporting at <a href="http://www.health.gov.il/research-fund">http://www.health.gov.il/research-fund</a>

<b>Italy – FRRB Fondazione Regionale per la Ricerca Biomedica</b>	
<b>Specific National/ Regional rules</b>	<b>FRRB funds ONLY human-related research activities (fundamental preclinical and clinical research)</b> Eligible applicants: <ul style="list-style-type: none"> <li>• Public or Private Italian IRCCS (Scientific Institutes for Health Research, Hospitalization and Health Care)</li> <li>• Public Health Care Providers (ASST)</li> <li>• Universities (<i>only in in partnership with one IRCCS, public or private, or an ASST located in Lombardy and requesting funding to FRRB</i>)</li> <li>• Research Institutes (<i>only in in partnership with one IRCCS, public or private, or an ASST located in Lombardy and requesting funding to FRRB</i>)</li> </ul> Please note : <ul style="list-style-type: none"> <li>• All applicants must be located in Lombardy .</li> <li>• Enterprises and for profit Organisations are NOT eligible.</li> <li>• MAXIMUM TWO PARTNERS from Lombardy PER PROJECT</li> </ul> No more than two partners from the same country are allowed per project.
<b>Eligible costs</b>	<b>Maximum € 500,000 per project</b> <b>MAXIMUM TWO PARTNERS from Lombardy PER PROJECT</b> Direct costs: <ul style="list-style-type: none"> <li>• Personnel (for public IRCCS and ASST, ONLY temporary contracts are eligible): max 50% of the total direct costs (<i>overheads and subcontracting costs excluded</i>)</li> <li>• Consumables, animals purchase, maintenance and breeding;</li> <li>• Equipment (on hire or eligible amortization rate);</li> <li>• Travel: max 10% of the total direct costs (<i>overheads and subcontracting costs excluded</i>)</li> <li>• Publications: max 5% of the total direct costs (<i>overheads and subcontracting costs excluded</i>)</li> <li>• Overheads: 20% flat rate calculated on direct costs (<i>Subcontracting costs excluded from this calculation</i>).</li> <li>• Subcontracting: max 20% of the total direct costs (<i>overheads costs excluded</i>)</li> </ul> FRRB will require the submission of a financial audit certificate together with the final financial report. This cost, to be included under the “Subcontracting” cost category will be eligible up to a maximum of € 8.000,00.

	Only costs generated over the lifetime of the project will be considered eligible.
<b>Additional documents required</b>	<p>According to internal procedures, Regional Foundation for Biomedical Research (FRRB) will grant an eligibility clearance to the potential applicants prior to the submission of the pre-proposals.</p> <p>The eligibility check will be based on the verification of a dedicated form ("<i>Eligibility check form</i>"), also available on the FRRB institutional website, to be completed by the Principal Investigator at least 10 working days before the pre-proposal submission deadline.</p> <p>FRRB will provide feedback on the "<i>Eligibility check form</i>" ONLY in case of major non-eligibility issues</p>
<b>Eligible One Health settings</b>	Only Human Health area is eligible for funding.
<b>Conditions clinical studies (if any)</b>	Allowed within the duration of the project
<b>Further information</b>	A Principal Investigator (PI) cannot simultaneously hold more than one FRRB grants. If a PI is currently a FRRB grant holder, s/he may apply for a JPIAMR grant but in case of award s/he will have to choose between one of the two grants. This rule applies only to PIs, not to team members.

<b>Italy – IT-MOH Italian Ministry of Health</b>	
<b>Specific National/ Regional rules</b>	<p>Only Scientific Institutes for Research, Hospitalisation and Healthcare (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati, IRCCS) and from Istituto Superiore di Sanità (ISS) are eligible.</p> <p>No academic and industrial partners are eligible.</p> <p>The simultaneous participation in proposals submitted to different transnational research calls 2021, funded by the It-MoH, is not allowed to Italian Principal Investigators or other research team members.</p> <p>MAXIMUM TWO PARTNERS funded by the It-MoH PER PROJECT (maximum two Italian partners for project)</p> <p>No more than two partners from the same country are allowed per project.</p>
<b>Eligible costs</b>	<p>Only costs generated during the lifetime of the project can be eligible.</p> <p>Personnel (only ad hoc contracts/consultants/fellowship, max 50% of the requested fund);</p> <p>Travel costs and subsistence allowances (max 10% of the requested fund);</p> <p>Equipment (rent/leasing only, no limit), consumables (no limit), dissemination of results (publications, meetings/workshops etc.- max 1% of the requested fund);</p> <p>Data handling and analysis (no limit);</p> <p>Overhead (maximum 10% of the requested fund). (All according to the national regulations). Travel expenses and subsistence allowances associated with training activities only linked to the project.</p> <p>Rules for subcontracting must be discussed with the It-MoH previously (20 days before the deadline of pre-proposal).i</p>
<b>Additional documents required</b>	<p>The Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the pre-proposals. To this end, it is mandatory that the applicants fill out and return a pre-eligibility (Italy_MOH_mandatory_pre-eligibility check form 2021) check form through IRCCS Scientific Directorate or Regional Office Health Research using WFR System 10 days before submitting their pre-proposals to the Joint Call Secretariat.</p> <p>If the Italian P.I. would like to include a subcontracting in the project, the pre-eligibility has to arrive to the Ministry 20 days before the deadline with the informative request.</p>

<b>Eligible One Health settings</b>	The Italian Ministry of Health funds ONLY human-related research activities (fundamental clinical research)
<b>Conditions clinical studies (if any)</b>	It MoH component clinical studies are eligible for funding as long as the costs are within the 250.000 € limits and allowed within the duration of the project
<b>Further information</b>	The funding of this projects are under the “Ricerca Corrente” IRCCS rules. Max 250,000 EUR per project

<b>Latvia – VIAA State Education Development Agency</b>	
<b>Specific National/ Regional rules</b>	<p>1. Funding of industrial partners is eligible only if they represent business enterprises entered into the Latvian Commercial registry, assumed they are eligible to do the specific research and are in possession of necessary resources in Latvia. The main activity should be in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting and audit requirements.</p> <p>2. The other category of partner eligible for funding by VIAA is Research institutions: Universities, research institutes, other research institutions – must be listed mandatory in the Latvian register of scientific institutions. They must comply with Research and knowledge-dissemination organization criteria (R651/2014).</p> <p>Any other type of participants is not covered by VIAA mandate.</p>
<b>Eligible costs</b>	<p>Per partner: 70,000 EUR/year, i.e. maximum grant per partner is 210,000 EUR for a 3-year project.</p> <ul style="list-style-type: none"> <li>• Personnel costs incl. taxes;</li> <li>• Consumables;</li> <li>• Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted;</li> <li>• Equipment (only depreciation costs);</li> <li>• Replaceable and fully consumable during project elements of equipment, materials and animals;</li> <li>• Travels (according to travel plan);</li> <li>• Indirect costs (up to 25% of direct costs excluding subcontracting).</li> </ul> <p>Costs must be research and innovation costs, there is no support for other activities</p> <p>Latvia allows max. 2 Latvian partners per proposal. In case of two Latvian partners per proposal, they shall be completely independent entities.</p>
<b>Additional documents required</b>	Applicants might be asked to provide additional information in order to assess their eligibility. Applicants are obliged to provide any information specified by Provisions of the Cabinet of ministers No 259, 26.05.2015 upon request.
<b>Eligible One Health settings</b>	Human health, animal health, environmental health
<b>Conditions clinical studies (if any)</b>	Allowed are early stage clinical studies carried out by an eligible Latvian project partner VIAA does not fund any kind of clinical partnerships

<b>Further information</b>	<p>See Provisions of the Cabinet of Ministers:  <a href="http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma">http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma</a></p> <p>They should be followed without any exception. All limits and conditions contained in the Provisions in relation to ERA-NET Cofund are an eligibility criteria for funding.</p> <p>Scientific and financial reports should be provided as requested by VIAA. To release the funding, duly signed Consortium Agreement must be presented to VIAA.</p>
----------------------------	---

<b>Lithuania – LMT Research Council of Lithuania</b>	
<b>Specific National/ Regional rules</b>	The proposals are submitted by the researcher(s) together with the eligible beneficiary institution. The principal investigator must be employed by the beneficiary institution for the duration of the project and his work load must be at least 20 hours multiplied by the duration of the project in months. Hourly rates approved by the Chairman of the Lithuanian Research Council must be applied for the personnel costs. All other general rules for competitive funding of Research Council of Lithuania apply: <a href="https://www.e-tar.lt/portal/lt/legalAct/Oa8bead0577611e9975f9c35aedfe438/asr">https://www.e-tar.lt/portal/lt/legalAct/Oa8bead0577611e9975f9c35aedfe438/asr</a>
<b>Eligible applicants</b>	Eligible for funding institutions are Lithuanian research and higher education institution which is included in the Register of Education and Research institutions and state healthcare institutions. Eligible institutions manages the state budget funds allocated to the project following the procedures stated in the legal acts, as well as representing the project partners (if applicable ‘project partner’ means public or private legal entity that, together with the eligible institution, created the conditions for project implementation). .
<b>Eligible costs</b>	Only costs generated during the lifetime of the project, related to project can be eligible: personnel, travel, consumables, subcontracting, contractual research, consultancy, equipment and instruments, dissemination of results, data handling and analysis, overheads (up to 30 % from the listed direct costs - personnel, travel, consumables, subcontracting, contractual research, consultancy). Max. grant amount 100 000 Eur
<b>Additional documents required</b>	No
<b>Eligible One Health settings</b>	All eligible
<b>Conditions clinical studies (if any)</b>	Clinical studies are allowed as long as project together with eligible beneficiary institution brings new research insights into the field.
<b>Further information</b>	<a href="https://www.e-tar.lt/portal/lt/legalAct/Oa8bead0577611e9975f9c35aedfe438/asr">https://www.e-tar.lt/portal/lt/legalAct/Oa8bead0577611e9975f9c35aedfe438/asr</a>

<b>Moldova – ANCD Agentia Nationala Pentru Cercetare Si Dezvoltare</b>	
<b>Specific National/ Regional rules</b>	The proposals are submitted by the researcher(s) together with the eligible beneficiary institution. The principal investigator must be employed by the beneficiary institution



	<p>for the duration of the project and his work load must not exceed 12 hours per day in all projects financed by ANCD. Remuneration in the project will be based on the national legislation.</p> <p>ANCD will avoid double funding and will not finance projects or part of projects that have been funded through other calls.</p> <p>In Moldova, the projects will be implemented by one MD organisation independent or in partnership with local public or private partners. Thus, for one project proposal the only one public research organisation can request funding.</p>
<b>Eligible applicants</b>	<p>Universities, research institutes, other public research institutions.</p> <p>Although private enterprises are not funded by the ANCD, the Moldovan industrial sector is welcome to participate in the transnational consortia using their own funds or obtaining funds from other sources.</p>
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>• Personnel costs for temporary employment contracts</li> <li>• Direct costs (VAT included) such as current costs, small scientific equipment, disposable materials, travelling expenses, coordination costs, and other costs that can be justified as necessary to carry out the proposed activities.</li> </ul> <p>The total envelop for this call is 200,000€; the lowest limit for the project proposals is 60,000€ and the highest limit is 100,00€.</p> <p>The final funding will take into account the transnational evaluation of the collaborative proposal and the financial resources available.</p>
<b>Additional documents required</b>	<p>No additional documents should be submitted to ANCD during the submission phase. In case a project is selected for funding, Moldovan partners will be invited to sign grant contracts. Successful MD project partners will have two month from the date they are notified of a positive funding decision to submit the grant contract completed.</p> <p><b>Reporting</b></p> <p>In addition to reporting requirements set out in the call document, standard ANCD reporting terms and conditions will apply. MD partners are expected to report on outputs and outcomes on a regular basis.</p>
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Conditions clinical studies (if any)</b>	No particular conditions
<b>Further information</b>	<p><b>National Call Secretariat</b></p> <p>For further information on national requirements, please contact:</p> <p><i>Dr Viorica Boaghi</i> Deputy General Director of ANCD Email: <a href="mailto:viorica.boaghi@ancd.gov.md">viorica.boaghi@ancd.gov.md</a></p> <p><i>Sveatoslav Postoronca</i> Senior advisor ANCD E-mail: <a href="mailto:sveatoslav.postoronca@ancd.gov.md">sveatoslav.postoronca@ancd.gov.md</a></p>

<b>Netherlands – ZonMw</b>	
<b>The Netherlands Organisation for Health Research and Development</b>	
<b>Specific National/ Regional rules</b>	<p>Only research organisations according to EC Framework for State aid for research and development and innovation (2014/C 198/01) are eligible for funding.</p> <p>See: <a href="https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=CELEX%3A52014XC0627%2801%29">https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=CELEX%3A52014XC0627%2801%29</a></p>

	<p><b>Note:</b> A limited part of the requested national budget can be used for outsourcing. Otherwise, parties other than mentioned above can only participate as a non-funded partner, and need to secure their own funding in order to be involved in a project. As a general rule, a minimum of 60% of the requested national budget needs to be allocated to research organisations.</p> <p>ZonMw will avoid double funding and will not finance projects or part of projects that have been funded through other calls. ZonMw will cross-check the proposals submitted to ZonMw through the national and international calls for possible demands of double funding.</p>
<p><b>Eligible costs</b></p>	<p>Relevant project expenses, such as:</p> <ul style="list-style-type: none"> <li>- Salary-related costs</li> <li>- Travel costs</li> <li>- Direct running costs</li> <li>- Dissemination and knowledge exchange costs</li> <li>- Datamanagement / data steward</li> <li>- Open access costs with a maximum of € 5000,-/project</li> </ul> <p>There will be a maximum of € 250.000 per consortium available (1 Dutch participant in the consortium: max. € 250.000, 2 Dutch participants in the consortium: max. € 250.000 for the both of them together).</p> <p>For more information, please consult the <a href="#">ZonMw terms and conditions</a> or your national contact person.</p>
<p><b>Additional documents required</b></p>	<p>Awarded projects will need to deliver a Consortium Agreement and Data Management Plan. With regards to the Consortium Agreement ZonMw requests an unsigned copy of the CA before the start of the project and a copy of the CA, signed by all partners, within 12 months after the project start date to assess the Dutch participation for compliance with the European law on state aid and ZonMw's <a href="#">general grant terms and conditions</a>.</p> <p>With regards to ZonMw, no grant will be awarded if arrangements between the collaborating Dutch partners (= parties involved in the research) would or could lead to the provision of unlawful state aid.</p> <p>If any co-financer of partner(s) of the research is not involved in the project as an executive partner within the consortium, then you must also submit the signed agreement setting out this co-financer's financial commitment (the sponsorship agreement). If ZonMw does not accept the consortium agreement and/or sponsorship agreement (proof of co-financing), no grant may be paid out.</p> <p>For further information and requirements, please check the <a href="#">ZonMw website</a>.</p> <p>We would appreciate and strongly recommend to make use of the template agreement on the ZonMw <a href="#">website</a>.</p> <p>If you have any questions about the consortium agreement / Intellectual Property (IP) rights, contact your IP/contract specialist, who is likely to work at your organisation's valorisation department or technology transfer office (TTO). You may also contact this specialist for advice on drawing up a consortium or sponsorship agreement. ZonMw advises you to involve this person in your application at the earliest possible stage. If granted, in the Dutch application system the <b>contact details</b> of the IP/contract specialist at the organisation with administrative responsibility need to be included.</p>

<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Conditions clinical studies (if any)</b>	Standard ZonMw Grant Conditions apply.
<b>Further information</b>	<ul style="list-style-type: none"> <li>- ZonMw will also fund Social Sciences.</li> <li>- In case the joint proposal is recommended for funding, Dutch applicants will have to submit a formal application through ZonMw ProjectNet.</li> <li>- Awards will be subject to standard ZonMw Grants Conditions.</li> <li>- Make sure to consult the ZonMw <a href="#">Open Access publication</a> and <a href="#">Data management</a> policies.</li> </ul>

<b>Norway – RCN The Research Council of Norway</b>	
<b>Specific National/ Regional rules</b>	See national guidelines for Researcher projects. Please note that you can only be partner or project manager on <i>one</i> application in this call.
<b>Eligible costs</b>	1.5 M EUR for the total 3-year period. 700,000 EUR per project for the total 3-year period
<b>Additional documents required</b>	No
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Conditions clinical studies (if any)</b>	Standard RCN Grant Conditions apply.
<b>Further information</b>	See national guidelines for Researcher projects. Please note that you can only be partner or project manager on <i>one</i> application in this call.

<b>Poland – NCN National Science Centre</b>	
<b>Specific National/ Regional rules</b>	<p>National rules for participation are given in the UNISONO resolution 137/2020 available here: <a href="https://ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2020/uchwala137_2020-zal1_ang.pdf">https://ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2020/uchwala137_2020-zal1_ang.pdf</a></p> <p>Please note:</p> <ul style="list-style-type: none"> <li>• project tasks to be carried out by Polish research teams may involve only basic research i.e. experimental or theoretical endeavours undertaken to gain new knowledge of the foundations of phenomena and observable facts, without any direct commercial use;</li> <li>• proposals may include application for state aid, except where a natural person applies for funding;</li> <li>• proposals may involve non-commercial clinical trials related to a medicinal product or a medical device;</li> </ul> <p>NCN funds projects that last either 24 or 36 months.</p>
<b>Eligible costs</b>	<p>All costs relevant, necessary and directly connected to the proposed research project including:</p> <ol style="list-style-type: none"> <li>1. <b>Personnel costs</b> – permanent and/or temporary; including post-doc positions and scholarships for PhD students;</li> <li>2. <b>Equipment:</b> up to 114 631 EUR (500,000 PLN) per unit;</li> <li>3. <b>Other direct costs:</b> materials, devices and software, outsourcing and subcontracting, travel and subsistence costs, visits and consultations, costs of publications, collective investigators;</li> <li>4. <b>Overheads/indirect costs:</b> there are two types of indirect costs, both calculated automatically:</li> </ol>

	<ul style="list-style-type: none"> <li>• general indirect costs - up to 20% of total direct costs of the project. General indirect costs include administrative personnel costs as well as costs of organizing conferences, workshops, seminars or meetings.</li> <li>• indirect costs of Open Access (publications and data) - up to 2% of total direct costs of the project</li> </ul> <p>The amount budgeted for indirect costs may not be increased during the course of a research project.</p> <p><b>EURO exchange rate: 1 EUR =4,3618 PLN</b></p>
<b>Additional documents required</b>	At the full proposal stage Polish applicants must submit their <b>national applications</b> in the ZSUN/OSF submission system. If one international project consortium includes partners from two or more different Polish institutions, these institutions must apply to NCN as a group of entities.
<b>Eligible One Health settings</b>	Human health, animal health, environmental health
<b>Conditions clinical studies (if any)</b>	NCN funds: <ul style="list-style-type: none"> <li>• medical experiments as defined in the Act of 5 December 1996, on the professions of doctor and dentist, non-commercial clinical trials that must be registered in Central Register of Clinical Trials (<a href="https://www.clinicaltrialsregister.eu/">https://www.clinicaltrialsregister.eu/</a>) under the Act of 6 September 2001 (as amended) Pharmaceutical Law or the Act of 20 May 2010 (as amended) on medical device</li> </ul>
<b>Further information</b>	<ul style="list-style-type: none"> <li>• NCN Open Access Policy: <a href="https://ncn.gov.pl/sites/default/files/pliki/zarzadzenia-dyrektora/zarzadzenieDyr-38_2020_ang.pdf#page=2">https://ncn.gov.pl/sites/default/files/pliki/zarzadzenia-dyrektora/zarzadzenieDyr-38_2020_ang.pdf#page=2</a></li> <li>• Information about Personal Data Processing at NCN: <a href="https://ncn.gov.pl/dane-osobowe?language=en">https://ncn.gov.pl/dane-osobowe?language=en</a>.</li> </ul>

<b>Spain – AEI</b> <b>Agencia Estatal de Investigacion</b>	
<b>Specific National/ Regional rules</b>	<p>The eligible entities for the AEI funding are:</p> <p>Non-profit research organizations (such as universities, public research institutions, technological centres and other private non-profit institutions performing RDI activities in Spain), as per <a href="#">PCI 2020</a> call.</p> <p>Although private enterprises are not funded by the AEI, the Spanish industrial sector is welcome to participate in the transnational consortia using their own funds or obtaining funds from the CDTI or other innovation and technological development funding agencies.</p> <p><b>Mandatory:</b></p> <p>The Spanish Principal Investigators (PIs) must be eligible according to the PCI calls and must have experience as investigators in projects funded by the <i>Plan Nacional I+D+i 2008-2011</i>, the <i>Plan Estatal I+D+i 2013-2016</i>, the <i>Plan Estatal I+D+i 2017-2020</i>, ERC Grants, European Framework Programmes or other relevant international programmes.</p> <p><b>Incompatibilities (these must be taken into account when participating in different ERA-Nets or other international initiatives):</b></p> <ul style="list-style-type: none"> <li>• Principal Investigators will not be eligible for funding if they apply in more than one proposal of this transnational joint call, in more than one proposal in the same PCI call (or equivalent) and in PCI calls of consecutive years.</li> <li>• Principal Investigators must remain unchanged between the proposal of this transnational joint call and the national PCI call (or equivalent).</li> </ul> <p>The AEI will avoid double funding and will not grant projects or parts of projects already funded through other national or EU calls.</p>

Call Text 13<sup>th</sup> JPIAMR transnational co-funded call for research projects within the ERA-NET JPIAMR ACTION

<p><b>Eligible costs</b></p>	<ul style="list-style-type: none"> <li>• Personnel costs for temporary employment contracts</li> <li>• Direct costs (VAT included) such as current costs, small scientific equipment, disposable materials, travelling expenses, coordination costs, and other costs that can be justified as necessary to carry out the proposed activities.</li> <li>• Overheads (maximum 20%)</li> <li>• Clinical trials (proofs of concept, proofs of principle) are not eligible for funding in the PCI call.</li> </ul> <p>The following funding limits are considered eligibility criteria. Proposals not respecting these limits could be declared ineligible:</p> <ul style="list-style-type: none"> <li>• If the Consortium is NOT LED by a Spanish Coordinator and: <ul style="list-style-type: none"> <li>• there is only one Spanish Partner in the proposal: € 175.000</li> <li>• there are two Spanish Partners in the proposal, the amount for both Partners is: € 225.000</li> </ul> </li> <li>• If the Consortium IS LED by a Spanish Coordinator and: <ul style="list-style-type: none"> <li>• there is only one Spanish Partner in the proposal acting as Coordinator: € 250.000</li> <li>• there are two Spanish Partners in the proposal and one is acting as Coordinator, the amount for both Partners is: € 300.000</li> </ul> </li> </ul> <p>IMPORTANT: A maximum of two Spanish Partners requesting funding to the AEI in the same proposal are allowed.</p> <p>Centers formed by different Spanish legal entities will be considered as a unique entity, and thus the maximum funding should not exceed the limits per proposal established above (for example, mixed centers).</p> <p>The final funding will take into account the transnational evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, and the financial resources available.</p>
<p><b>Additional documents required</b></p>	
<p><b>Further information</b></p>	<p><b>Instrument for funding the Spanish groups</b></p> <p>The instrument for funding the Spanish groups is being redesigned for simplification. The current instrument, the Spanish call on RDI projects “International Joint programming (PCI)”, could be replaced in 2021. Nevertheless, applicants are encouraged to consult the PCI 2020 call, since the requirements will be similar.</p> <p><b>Funding Programme:</b></p> <p>The framework for this funding action is the <i>Plan Estatal de Investigación Científica, Técnica e Innovación 2021-2023</i>. On a national level, the Call will be managed by the <u>Subdivisión de Programas Científico-Técnicos Transversales, Fortalecimiento y Excelencia</u> of the AEI.</p> <p><b>Data Protection:</b></p> <p>By submitting a grant application to the AEI, the applicants consent to communication of the data contained in the application to other public administrations, with the aim of further processing of the data for historical, statistical or scientific purposes, within the framework of the Organic Law 3/2018, of December 5, on Personal Data Protection and Guarantee of Digital Rights.</p> <p><b>Mandatory acknowledgement:</b></p> <p>Any publication or dissemination activity resulting from the granted projects must acknowledge funding by the Agencia Estatal de Investigación: “Project (reference nº XX) funded by the Agencia Estatal de Investigación through the PCI XX call (or its equivalent)”.</p>

	<ul style="list-style-type: none"> <li>Principal Investigators must remain unchanged between the proposal of this transnational joint call and the national PCI call (or equivalent).</li> </ul> <p>The AEI will avoid double funding and will not grant projects or parts of projects already funded through other national or EU calls.</p>
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>Personnel costs for temporary employment contracts</li> <li>Direct costs (VAT included) such as current costs, small scientific equipment, disposable materials, travelling expenses, coordination costs, and other costs that can be justified as necessary to carry out the proposed activities.</li> <li>Clinical trials (proofs of concept, proofs of principle) are not eligible for funding in the PCI call.</li> </ul> <p>The following funding limits are considered eligibility criteria. Proposals not respecting these limits could be declared ineligible:</p> <ul style="list-style-type: none"> <li>If the Consortium is NOT LED by a Spanish Coordinator and: <ul style="list-style-type: none"> <li>there is only one Spanish Partner in the proposal: € 175.000</li> <li>there are two Spanish Partners in the proposal, the amount for both Partners is: € 225.000</li> </ul> </li> <li>If the Consortium IS LED by a Spanish Coordinator and: <ul style="list-style-type: none"> <li>there is only one Spanish Partner in the proposal acting as Coordinator: € 250.000</li> <li>there are two Spanish Partners in the proposal and one is acting as Coordinator, the amount for both Partners is: € 300.000</li> </ul> </li> </ul> <p>IMPORTANT: A maximum of two Spanish Partners requesting funding to the AEI in the same proposal are allowed.</p> <p>Centers formed by different Spanish legal entities will be considered as a unique entity, and thus the maximum funding should not exceed the limits per proposal established above (for example, mixed centers).</p> <p>The final funding will take into account the transnational evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, and the financial resources available.</p>
<b>Additional documents required</b>	
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Conditions clinical studies (if any)</b>	Clinical trials (proofs of concept, proofs of principle) are not eligible for funding in the PCI call.
<b>Further information</b>	<p><b>Instrument for funding the Spanish groups</b></p> <p>The instrument for funding the Spanish groups is being redesigned for simplification.</p> <p>The current instrument, the Spanish call on RDI projects “International Joint programming (PCI)”, could be replaced in 2021.</p> <p>Nevertheless, applicants are encouraged to consult the PCI 2020 call, since the requirements will be similar.</p> <p><b>Funding Programme:</b></p> <p>The framework for this funding action is the <i>Plan Estatal de Investigación Científica, Técnica e Innovación 2021-2023</i>. On a national level, the Call will be</p>

	<p>managed by the <u>Subdivisión de Programas Científico-Técnicos Transversales, Fortalecimiento y Excelencia</u> of the AEI.</p> <p><b>Data Protection:</b> By submitting a grant application to the AEI, the applicants consent to communication of the data contained in the application to other public administrations, with the aim of further processing of the data for historical, statistical or scientific purposes, within the framework of the Organic Law 3/2018, of December 5, on Personal Data Protection and Guarantee of Digital Rights.</p> <p><b>Mandatory acknowledgement:</b> Any publication or dissemination activity resulting from the granted projects must acknowledge funding by the Agencia Estatal de Investigación: “Project (reference nº XX) funded by the Agencia Estatal de Investigación through the PCI XX call (or its equivalent)”.</p>
--	--

<p><b>Spain – ISCIII</b> <b>National Institute of Health Carlos III</b></p>	
<p><b>Specific National/ Regional rules</b></p>	<p><b>Funding Program:</b> <u>Acción Estratégica en Salud (AES)</u>  <b>Initial funding pre-commitment:</b> 500.000 €  <b>Number of groups</b> that could be funded: 2-3  <b>Maximum grant duration:</b> 36 months  <b>Maximum funding per awarded Spanish project partner:</b></p> <ul style="list-style-type: none"> <li>• Up to 175.000 € per partner (overheads included)</li> <li>• Up to 250.000 € per coordinator (overheads included)</li> </ul> <p><b>Eligible institutions:</b></p> <ul style="list-style-type: none"> <li>• <b>Hospitals, primary health care or public health administration of the Spanish National Health System (SNS).</b> These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation’s statutes maybe submitted).</li> <li>• <b>Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS).</b> Accredited according to the RD 339/2004, of February 27th or RD 279/2016</li> <li>• <b>CIBER or CIBERNED</b> Team members applying to the call must be from at least two groups belonging to CIBER in two different home institutions and one of these two must be a Hospital, primary health care or public health administration of the Spanish National Health System (<b>SNS</b>) or <b>IIS</b>.</li> <li>• <b>Academia or Other Research Centers.</b> These entities should apply to AEI. If applying to ISCIII they could only participate if they apply together with Hospitals, primary health care or public health settings of the <b>SNS</b> or <b>IIS</b> in the same proposal. It is not allowed to apply independently, thus there must be two beneficiary Spanish institutions requesting funding to ISCIII in the same proposal.</li> <li>• <b>Applicants from ISCIII</b> are eligible. Eligibility criteria from AESI 2021 apply</li> </ul> <p><b>Eligibility of PI and team members</b></p> <ul style="list-style-type: none"> <li>• <b>Principal Investigators (PIs)</b> can only participate in one proposal.</li> <li>• The Principal Investigator (PI) and all members of the research group must belong to the eligible institution or be affiliated to CIBER, CIBERNED or an IIS</li> <li>• <b>Excluded</b> personnel as Principal Investigator (PI): Those undergoing a <u>postgraduate training in Health Specialization</u> (MIR, FIR, QIR, BIR, PIR). Those undergoing <u>research training</u> (e.g. PhD students, or “Río</li> </ul>

	<p>Hortega” contracts). <u>Researchers contracted by a RETIC</u>. Those undergoing <u>postdoctoral training</u> (e.g. “Sara Borrell” or “Juan de la Cierva” contracts).</p> <p><b>Note:</b></p> <ul style="list-style-type: none"> <li>• Same institution cannot participate with more than one partner in the same project proposal.</li> <li>• Only one PI per beneficiary institution may be funded within the same proposal.</li> <li>• Researches with ongoing AMR projects in <b>2022</b> cannot apply to the current call unless the alive project or the new application is as Coordinator</li> </ul> <p>There is no other incompatibility with AES 2021.</p>
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>• Personnel costs for temporary employment contracts (scholarships are not eligible) according to AES 2021.</li> <li>• Current costs, small scientific equipment, consumables, disposable materials, traveling expenses and other costs than can be justified as necessary to carry out the proposed activities.</li> </ul> <p>Overheads: up 21% of the direct (according to AES 2021)</p>
<b>Additional documents required</b>	<p>National applications will be required by ISCIII. Spanish Applicants should periodically check in the web page of ISCIII if they are qualified. ISCIII may not send invitations to the mandatory national phase.</p> <p><a href="https://www.isciii.es/QueHacemos/Financiacion/Paginas/Accion-Estrategica-en-Salud.aspx">https://www.isciii.es/QueHacemos/Financiacion/Paginas/Accion-Estrategica-en-Salud.aspx</a></p>
<b>Eligible One Health settings</b>	<p>Human health. Animal health could be funded by ISCIII if the proposal is related with zoonotic diseases. Environment can only be funded if it has direct connection with human health.</p>
<b>Conditions clinical studies (if any)</b>	<p>Spanish groups participating in a proposal performing a clinical study are encouraged to include as members of the team personnel from a Clinical Trials Central Unit (Unidades de Investigación Clínica y Ensayos Clínicos - <b>UICEC</b>) of the Spanish Clinical Research Network (<b>SCReN</b>) that participates in ECRIN-ERIC. Find <a href="#">here</a> the list of UICECs. For additional information please contact: <a href="mailto:sectec.scren.hcsc@salud.madrid.org">sectec.scren.hcsc@salud.madrid.org</a> or Tel.: (+34) 91 330 38 58</p>
<b>Further information</b>	<ul style="list-style-type: none"> <li>• Due to administrative and legal regulations, ISCIII declares the end of <u>September 2021 as national deadline</u> for the decision on fundable project consortia which include Spanish partners to be funded by ISCIII. Any concerned applicant in a proposal for which no final decision has been made by the deadline, could be declared not fundable by ISCIII.</li> <li>• Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the “ELIXIR Core Data Resources” or if non-European repositories or data bases they must be certified by <b>ELIXIR</b> or the US National Center for Biotechnology Information (<b>NCBI</b>).</li> </ul> <p>ISCIII may no fund project that requires the construction of new repositories without decommissioning plans or ensured sustainability after the project’s end.</p>



Sweden – Sida Swedish International Development Cooperation Agency	
Specific National/ Regional rules	<p><b>Eligible institutions:</b> Sida will support the participation of researchers from low-income countries in sub-Saharan Africa, and other sub-Saharan African countries where Sweden has bilateral development cooperation.</p> <p>Institutions eligible to apply are Africa-based domestic universities or other academic research institutions, including non-profit organizations and international organizations, in the following countries:</p> <p><b>Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros, Congo (Dem. Rep.), Eritrea, Ethiopia, The Gambia, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, Niger, Rwanda, Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Tanzania, Togo, Uganda, Zambia, Zimbabwe</b></p> <p>Profit-making organizations are <b>not</b> eligible to receive Sida funding within this initiative.</p> <p><b>Eligible applicants:</b> African researchers employed by domestic universities or other academic research institutions, including non-profit organizations and international organizations, in the countries specified above are eligible to apply.</p> <p>Researchers from profit-making organizations are <b>not</b> eligible to receive Sida funding within this initiative.</p> <p>Researchers may only be listed as a project coordinator or research partner on <b>one</b> project application. However, multiple submissions from multiple projects with researchers based at the same institution are allowed.</p>
Eligible costs	<p>Eligible costs include salaries, consumables, equipment, travel and indirect costs.</p> <p>Grant funds may not be used to reimburse expenses incurred prior to the project start date.</p> <p>Sida will not fund projects or parts of projects that have been funded through other calls.</p> <p>No grantee is permitted to make sub-grants, but all grantees will be permitted to contract for services, up to a maximum of 20.000 Euro. Please be aware that this limit applies to funds paid by an awardee to any other organization (or an individual employed at another organization) as a subcontractor.</p> <p>Maximum budget per Sida partner is <b>250.000 Euro</b>, and up to <b>350.000 Euro</b> if the Sida partner is the coordinator of a proposal. A maximum of 2 partners eligible for Sida funding may request funding from Sida within a consortium.</p>
Additional documents required	<p>Grants to project coordinators/partners funded by Sida can only be administered by a university or other academic research institution.</p> <p>General conditions applicable to grants from Sida to NGO:s regarding project/programme support will apply to all institutions considered for a grant (<b><i>this document is accessible through the <a href="#">call page</a></i></b>).</p> <p>Before, deciding on grant funding, the capacity of each applicant's institution to administrate funds will be assessed according to Sidas regulations for contribution management, and the projects' adherence to the Swedish strategy for research cooperation and research in development cooperation;</p>

	<a href="https://www.regeringen.se/49f23e/contentassets/35640f803c554f5abe17800242c5bcb3/strategi-for-forskningssamarbete-pdf-for-webb-eng-2.pdf">https://www.regeringen.se/49f23e/contentassets/35640f803c554f5abe17800242c5bcb3/strategi-for-forskningssamarbete-pdf-for-webb-eng-2.pdf</a> .
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Conditions clinical studies (if any)</b>	No particular conditions.
<b>Further information</b>	Individuals that are members of projects invited to make a full proposal may be required to submit additional information that pertains to their specific work and/or budget within the research consortium to Sida, or a designated partner organization.

<b>Sweden – SRC Swedish Research Council</b>	
<b>Specific National/ Regional rules</b>	<ul style="list-style-type: none"> <li>• The applicant must be an individual researcher holding a PhD. Only researchers at an administrating organisation approved by the Swedish Research Council may apply. Please refer to general applicant eligibility requirements found <a href="#">here</a>. The applicant may not have an ongoing JPIAMR project grant, or any other project grant concerning the same project concept, funded by the Council, at the start of the grant period.</li> <li>• All Swedish applicants are encouraged to communicate with the JPIAMR national contact person regarding their intention to participate in the call, before submission of the consortium application.</li> <li>• Grant amount: Max. 3 500 000 SEK (approx. 340 000 Euro) per consortium with max 2 Swedish partners. Min. 1 200 000 SEK (approx. 115 000 EUR) per partner. Max 5 000 000 SEK (approx. 470 000 Euro) if a Swedish participant is the coordinator of the consortium. No funding of industrial partners.</li> <li>• You can only take part in one consortium within this call, either as coordinator or partner.</li> <li>• All Swedish project leaders participating in the call for support from the Swedish Research Council shall also submit a parallel application using the Swedish Research Council’s application system Prisma. The application form in Prisma can be reached from the call text at the SRC website.</li> </ul> <p><b>Parallel application is a mandatory eligibility criterion. Failure to submit the parallel application to the Swedish Research Council before the deadline of the Prisma call may result in the Swedish partner being declared ineligible.</b></p>
<b>Eligible costs</b>	<p>The project grant may be used to fund all types of project-related costs, such as salaries (including your own salary, however no more than corresponding to the person’s activity level in the project), running costs (such as consumables, travel including stays at research facilities, publication costs and minor equipment), premises and depreciation costs.</p> <p>Grants may not be used for scholarships. If a doctoral student participates, project funds may not be paid out as salary during teaching or other departmental duties.</p>
<b>Additional documents required</b>	
<b>Eligible One Health settings</b>	Human health
<b>Conditions clinical studies (if any)</b>	No particular conditions.
<b>Further information</b>	See national call texts in <a href="#">Swedish</a> and <a href="#">English</a> for all national requirements.

United Kingdom – UKRI United Kingdom Research and Innovation	
<b>Specific National/ Regional rules</b>	<p>UKRI, through MRC, BBSRC and NERC, is supporting the JPIAMR-ACTION call for One Health interventions to prevent or reduce the development and transmission of antimicrobial resistance (AMR) and encourage the UK AMR research community to apply for funding as part of transnational consortia. Awards will be made through MRC on behalf of the three UKRI Councils to successful UK applicants of transnational consortia will be required to upload their application of to Je-S within 1 month of the notice of award. Funding will be allocated in accordance with the usual Council remit areas commensurate with the level of funding contributed by each Council.</p> <p>Following these requirements, in addition to those set out in the main call text, is mandatory.</p> <p><b>Funding</b> Subject to conditions of eligibility and peer review being fully met, up to €2.5M will be available to UK researchers for this call.</p> <p>We anticipate supporting 5-7 applications from the UK budget available for this call. Individual consortia may request up to €500k UK funding per application.</p> <p>The UK component of applications should be costed on the basis of full economic costs (fEC). If the grant is awarded, funding will be provided on the basis of normal Council funding policy. The submitting organisations must agree to find the balance of fEC for the project from other resources.</p> <p><b>Eligibility</b> It is expected that applications submitted to this call will be multidisciplinary transnational research consortia addressing challenges in human, animal, and/or environment One Health domains, as defined in the main call text.</p> <p>Standard UKRI eligibility criteria will be applied to the UK components of applications. Higher Education Institutions (HEIs), Research Council Institutes (RCIs) and Independent Research Organisations (IROs) that are normally eligible to UKRI funding can apply.</p> <p>UK applicants can only submit a single pre-proposal as coordinator but may join other consortia as a partner.</p> <p>Full details of eligibility for Research Council funding can be found on the UKRI website: <a href="https://www.ukri.org/funding/how-to-apply/eligibility/">https://www.ukri.org/funding/how-to-apply/eligibility/</a></p> <p>Potential applicants are strongly advised to contact the National Call Secretariat or the UK National contact as detailed in Annex A of the Call in advance of making an application to resolve any eligibility queries.</p> <p><b>Industrial collaboration</b> Standard terms and conditions for industrial collaboration apply. Applicants who intend to collaborate with industrial or other non-academic partners should note that any costs incurred, direct or otherwise, by these partners cannot be met by UKRI Research Councils. Costs incurred by the UK academic partner as a direct result of working with other consortium partners (such as visits to labs or exchange of materials) can be requested.</p>

	<p>All applications involving industrial partners should complete an MRC Industry Collaboration Agreement (MICA) form, as detailed at <a href="http://www.mrc.ac.uk/innovation/mrc-industry-collaboration-agreement-mica/">http://www.mrc.ac.uk/innovation/mrc-industry-collaboration-agreement-mica/</a>.</p> <p><b>Reporting</b> In addition to reporting requirements set out in the call document, standard UKRI reporting terms and conditions will apply. UK partners are expected to report on outputs and outcomes on a regular basis (and for at least five years post-completion) through Researchfish.</p> <p>Any publications (including academic papers and press releases) or other dissemination activities resulting from research funded through this call must acknowledge UKRI co-funding and must be communicated to JPIAMR <a href="mailto:secretariat.jpiamr@vr.se">secretariat.jpiamr@vr.se</a> and UKRI <a href="mailto:press@ukri.org">press@ukri.org</a> at least one week prior to the event.</p>
<b>Eligible costs</b>	<p>Eligible costs include project-related costs incurred after the award start date such as staff and investigator costs, travel and subsistence, consumables, estates and indirect costs as per UKRI fEC rules.</p> <p>PhD students <u>cannot</u> be funded as part of a standard collaborative research proposal.</p> <p>Publication costs are <u>not</u> eligible under current UKRI funding rules as they are covered through a separate mechanism.</p> <p>MRC can fund overseas costs (developed and LMIC) relevant to improving human health but please note that any funding for overseas costs requested from the MRC budget should not exceed 30% of the UK costs and will come from the £500k threshold of UK funding per project. Neither BBSRC nor NERC will fund overseas costs.</p> <p>A full list of eligible costs can be found on the appropriate Council website:  <b>BBSRC:</b> <a href="https://bbsrc.ukri.org/funding/apply/application-guidance/">https://bbsrc.ukri.org/funding/apply/application-guidance/</a>  <b>MRC:</b> <a href="https://mrc.ukri.org/funding/guidance-for-applicants/resources/">https://mrc.ukri.org/funding/guidance-for-applicants/resources/</a>  <b>NERC:</b>  <a href="https://nerc.ukri.org/funding/application/howtoapply/forms/grantshandbook/">https://nerc.ukri.org/funding/application/howtoapply/forms/grantshandbook/</a></p>
<b>Additional documents required</b>	<p>Costs should be included as pounds sterling (GBP) on the proforma (see UKRI website call text) and included on the application as Euros using an exchange rate of 1.08 Euros per GBP. The total amount requested must be equivalent to the % fEC that is paid by the appropriate Research Council.</p> <p>Applicants should include a statement to confirm the exchange rate used, and that costs are entered at the appropriate fEC rate for the RO and normal Council funding policy.</p> <p>Applications involving human participation in clinical studies may be required to complete a SoECAT if invited for a full application.</p>
<b>Eligible One Health settings</b>	All One Health settings including humans, animals, plants, and the environment
<b>Conditions clinical studies (if any)</b>	UK components of phase I or IIa clinical trials are eligible for funding as long as the costs are within the £500k UK limit. Any application that includes excess treatment costs for studies involving human participants will be required to complete a SoECAT if invited for a full application. Please see the MRC guidance for applicants for further information.

<p><b>Further information</b></p>	<p><b>Specific national regulations and guidelines</b></p> <p>UK applicants invited to prepare a full proposal will also be asked to complete and submit a detailed proforma to clearly justify the requested resources, and to ensure that their proposal complies with <a href="#">UKRI standard terms &amp; conditions</a>. Further details and a copy of the proforma will be provided when full proposals are invited.</p> <p>Successful UK project partners will have one month from the date they are notified of a positive funding decision to submit a formal application through Je-S, which will include the costing proforma as above. The UK project partners' application through Je-S will not be subject to further peer review.</p> <p>UK grant holders are required to comply with UKRI <a href="#">Data Sharing</a> and <a href="#">Open Access</a> policies.</p> <p>Awards will be subject to standard <a href="#">UKRI Terms and Conditions</a>.</p> <p>UK funding for any application involving an industrial partner will not be released until a signed Consortium Agreement is received by MRC.</p>
-----------------------------------	---